



UNITED STATES DISTRICT COURT
DISTRICT OF ARIZONA

CIVIL EXHIBIT LIST

☐ Preliminary Injunction ☐ TRO ☐ Non-Jury Trial ☒ Jury Trial

Case Number MD-15-02641-PHX-DGC Judge Code 7020 Date Sept. 18, 2018

Lisa Hyde, et al. vs. C.R. Bard, Inc. and Bard Peripheral Vascular

☒ Plaintiff/Petitioner ☐ Defendant/Respondent

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1			11/4/1996 FDA 510(k) Not Substantial Equivalent letter for NMT Medical SNF 510(k) application
2			1/10/1997 NMT Medical 510(k) application for straight line SNF
3			12/19/1997 NMT Medical R&D Standard Operating Procedure/Doc#: RD-SOP-040-02; RNF Clot Capturing Study
4			3/20/1998 The New 510(k) Paradigm
5			3/23/1998 RD-RPT-041; Feasibility Animal Study
6			4/8/1998 NMT Medical Summary of Animal Study for FDA
7			4/13/1998 R&D Technical Report; Feasibility Animal Study, RD-RPT-045
8			4/30/1998 NMT Medical RNF Animal Study
9			6/12/1998 Meeting regarding NMT Medical Sheep Study
10			6/15/1998 Analysis of RNF migration resistance
11			11/19/1998 RNF Design Animal Verification Study, In-Vivo Occlusion Migration Resistance Data Sheets for 88 lb. sheep
12			11/19/1998 RNF Design Animal Verification Study, In-Vivo Occlusion Migration Resistance Data Sheets for 90 lb. sheep

Exhibit No.	Marked for ID	Admitted in Evidence	Description
13			12/2/1998 R&D Standard Operating Procedure, RD-SOP-051.00;RNF Design Verification: In-vivo Evaluation for Permanent Indication
14			12/15/1998 Design comparisons between SNF and RNF
15			12/17/1998 NMT Medical R&D Standard Operating Procedure/Doc #: RD-SOP-052.00;RNF Design Verification: In Vivo Evaluation for long term removal
16			2/17/1999 NMT Medical R&D Standard Operating Procedure, RNF Evaluation of Creep Resistance of the Removable Nitinol Vena Cava Filter Hooks
17			2/23/1999 In-Vivo Evaluation of the Removable Nitinol Filter System for Permanent and Intra-Procedural Removal Indications
18			4/29/1999 Recommended Reporting Standards for Vena Cava Filter Placement and Patient Follow-Up; Greenfield, et al.
19			5/20/1999 Risk Estimation Guidelines for HHES
20			6/1/1999 NMT Medical RNF Meeting Notes re fatigue testing
21			6/27/1999 Standard Operating Procedure, RNF Migration Study, Design Verification
22			6/28/1999 EnduraTEC Corrosion / Fatigue testing of RNF - Design verification
23			6/28/1999 R&D Standard Operating Procedure RD-SOP-054.00;EnduraTEC Corrosion / Fatigue testing of RNF - Design verification
24			6/28/1999 R&D Standard Operating Procedure RD-SOP-054.00;EnduraTEC Corrosion / Fatigue testing of RNF - Design verification
25			07/29/1999 NMT R&D SOP 72, RNF Design Verification Radial Strength

Exhibit No.	Marked for ID	Admitted in Evidence	Description
26			Duplicate - see Ex 25 - 7/29/1999 NMT Medical R&D Standard Operating Procedure/Doc #: RD-SOP-072; Evaluation of the radial strength of Removable Nitinol Vena Cava Filter
27			7/29/1999 NMT Medical R&D Standard Operating Procedure/Doc#: RD-SOP-071; Evaluation of the hook strength of the Removable Nitinol Vena Cava Filter
28			8/1/1999 Production Timeline
29			8/4/1999 R&D Technical Report RD-RPT-099; EnduraTEC Corrosion / Fatigue testing of RNF - Design verification
30			8/5/1999 NMT Medical R&D Technical Report; Migration Resistance Study
31			8/9/1999 R&D Technical Report RD-RPT-102 with attachments regarding radial strength
32			8/9/1999 RNF Hook Strength - Design verification
33			8/12/1999 NMT Medical R&D Technical Report/Doc #:RD-RPT-095; Test Results for RD-SOP-057-Simulated Use/Determine capability to deliver removable filter in an in-vivo environment
34			8/18/1999 NMT Medical/BPT Update Meeting Agenda
35			8/19/1999 Pathology Report: In-Vivo Evaluation of the Removable Nitinol Filter System for Permanent and Intra-Procedural Removable Indications
36			08/23/1999 NMT R&D Tech Report, RD-RPT-104, Analysis of RNF Migration Resistance
37			8/23/1999 Analysis of RNF migration resistance
38			9/24/1999 NMT Medical Final Pathology Report regarding 15 Sheep
39			9/24/1999 NMT Medical Final Pathology Report regarding 8 Sheep
40			10/4/1999 NMT Medical Design Inputs
41			11/1/1999 Special 510(k) Submission for Recovery Filter

Exhibit No.	Marked for ID	Admitted in Evidence	Description
42			12/10/1999 FDA 510(k) Not Substantial Equivalent Letter for NMT Medical 510(k) RNF application
43			12/14/1999 Material Routing
44			12/15/1999 RNF Design History File Table of Contents
45			2/1/2000 R&D Technical Report RD-RPT-120-Draft; Fatigue Evaluation of RNF Draft
46			2/22/2000 Pathology Report for NMT Medical regarding sheep study for long term removal indication
47			3/8/2000 R&D Standard Operating Procedure RD-SOP-054.01;EnduraTEC Corrosion / Fatigue testing of RNF - Design verification
48			4/24/2000 NMT Medical R&D Technical Report/DOC#: RD-RPT-121;In-Vivo technical testing of RNF for long-term removal
49			8/14/2000 NMT Medical R&D SOP -035.03; Migration resistance evaluation of an IVC filter with an in-vitro model of the vena cava
50			6/5/2001 SNF substantial equivalence report
51			06/20/2001 NMT R&D Tech Report, RD-RPT-137, SNF Performance Specification Testing: NMT Filters
52			10/12/2001 Email from Bob Mellen to Bill Lonfield re Global Filter Sales through 9/30/2001 and distribution list
53			10/17/2001 Evaluation of RNF hook strength test
54			1/21/2002 Memo from Uelmen to Luttrell re: Vena Cava Filter MDR reporting criteria
55			4/1/2002 Recovery IFU 04/02 rev 0
56			4/18/2002 Email from Vierling to Murray re RNF filter
57			7/23/2002 Clot trapping efficiency
58			7/23/2002 Recovery: Special 510(k)

Exhibit No.	Marked for ID	Admitted in Evidence	Description
59			8/30/2002 IMPRA letter to FDA addressing concerns with RNF
60			11/5/2002 Filter Meeting Minutes discussing permanent Recovery 510(k)
61			12/1/2002 Recovery IFU 12/02 rev 1
62			12/13/2002 Email from Kowalczyk to Edwards regarding RNF
63			12/13/2002 Email from Stokoe to Walcott regarding Recovery Filter Incident
64			12/13/2002 Proposed Process Validation Plan for RNF.
65			4/17/2003 Email string from Carr to Locke re SNF IFU Final
66			7/23/2003 Emails between Edwards and Kennell regarding IFU language
67			7/25/2003 Abbreviated 510(k) for Recovery
68			8/23/2003 Email from Edwards to Walcott about complaints from Murray Asch
69			9/19/2003 Email between Janet Hudnall and John Kaufman
70			10/25/2003 Email between Janet Hudnall and John Kaufman
71			12/10/2003 E-mail from DeCant regarding Special Design Review Meeting
72			12/30/2003 Email string from Hudall to Kaufman re questions
73			2004 MAUDE data and filter sales as of Q1 2004
74			2004 Recovery filter marketing brochure, Rev. 0
75			2/12/2004 Email from Tessmer, RNF Ground Nitinol Wire Supplier Qualification Protocol
76			2/12/2004 Recovery Filter and Recovery Cone IFUs
77			2/13/2004 Filter Migration Meeting Minutes with attachments
78			2/17/2004 Protocol for migration resistance testing; email and TPR-04-02-02

Exhibit No.	Marked for ID	Admitted in Evidence	Description
79		9-21-18	2/19/2004 Characterization of RNF - Migration resistance; TPR-04-02-02 REV 0 Test protocol for migration resistance Characterization of RNF - Migration resistance
80			2/20/2004 Email from Lehmann to Kellee, et al
81			2/20/2004 Email regarding IVC dimensional variability
82			2/24/2004 Email from Hudnall and to Uelmen, cc Carr regarding filter complaint
83			2/27/2004 Meeting Agenda for 2-27-2004; Meeting Agenda for 2/27/2004 Migration Failure Investigation Team meeting. Proposed fault tree analysis to determine cause of migration.
84			3/2004 through 12/31/07 Filter Complaint Summary, complaint sales data
85			3/4/2004 Recovery Filter Characterization Testing Help
86			3/4/2004 RNF; Design failure modes and effect analysis for recovery filter BPVE-01-00412819: DFMEA 070010, rev 3 Update and Email
87			3/8/2004 Migration Meeting Minutes of March 4, 2004
88			3/10/2004 Email regarding Lehmann's HHE for Miami Baptist Hospital
89			3/12/2004 CR Bard Recovery Filter Questions
90			3/13/2004 Email: re Recovery Filter Follow up at CHUM; email string Re Recovery Filter Follow up at CHUM evidence of Doctor shopping
91			3/16/2004 Re: Final Proposed Email Notification; Email re: Proposed final sales communique
92			3/19/2004 Comparative Test Report ETR-04-03-19 Rev 0 Radial Strength of the RNF

Exhibit No.	Marked for ID	Admitted in Evidence	Description
93			3/25/2004 Draft of Agenda for Filter Migration Physician Review Panel 3-26-2004; Email and Draft of Agenda for Filter Migration Physician Review Panel 3-26-2004
94			3/29/2004 The Buckingham Research Group; Buckingham Research Group notes on SIR annual meeting
95			4/5/2004 ETR-04-03-18 Rev 0; Characterization of Recovery Migration Resistance when filter is tilted
96			4/6/2004 Email between Janet Hudnall and John Kaufman
97			4/7/2004 G1A concept and development time line; G1A concept and development time line
98			4/14/2004 Email from Cindi Walcott to Uelmen and Edwards regarding Recovery filter migration
99			4/21/2004 Characterization of Recovery Migration Resistance in Comparison to Competitive Product Phase 1, ETR-04-03-02 Rev 0 Phase 1
100			4/21/2004 Email string from Hudnall and Edwards re voicemail to sales force
101			4/23/2004 Email from Carr to Weiland regarding MAUDE data
102			4/23/2004 Email HHE
103			4/23/2004 Email re filter sales and MAUDE data as of Q1 2004
104			4/26/2004 BPV/ANGIOMED New product development Review meeting
105			4/26/2004 CAPA Meeting Minutes from 4/26/2004
106			4/30/2004 Recovery Filter Crisis Communications by Hill & Knowlton
107			5/1/2004 Email between Janet Hudnall and John Kaufman
108			5/4/2004 Email between Janet Hudnall and John Kaufman
109			5/6/2004 Email from Kaufman to Hudnall re Independent Review Panel

Exhibit No.	Marked for ID	Admitted in Evidence	Description
110			5/12/2004 RNF Jigs
111			5/13/2004 Email re filter complaint death
112			5/14/2004 MCVI Presentation ("Media Crisis")
113			5/17/2004 Updated Maude database & SPA-04-04-02 through Q1 2004
114			5/26/2004 Jigs with modified top ring
115			6/4/2004 Email and complaint migration data
116			6/4/2004 Thromboembolic Disease State Review per patient type
117			6/9/2004 Email filter improvements
118			6/9/2004 Email from Jason Greer forwarding filter placement billing codes
119			6/9/2004 Email from Carr to Tessmer re Filter Improvement DOE
120			6/25/2004 CR Bard Chicago roundtable discussion
121			6/25/2004 Meeting Summary of Thromboembolic Disease & Vena Cava Filters: A Multidisciplinary Focus Group
122			6/26/2004 Q4 Maude Update
123			6/28/2004 Email chain between Chanduszeko and Carr re hook strength and sizes
124			6/28/2004 RNF Filter, Non-Linear stress analysis during delivery tube insertion
125			6/29/2004 Email to Ciaverella re John Lehmann's availability and health risk rating for fracture in R-002 RAP
126			7/1/2004 Email between Janet Hudnall and John Kaufman
127			7/6/2004 Email from Vincelli setting up conference call about RF
128			7/6/2004 Email re Recovery IFU draft
129			7/7/2004 Email from Carr Cindi Walcott re testing for detached limbs, RAP & HHE
130			7/8/2004 Email from Hudnall with revisions to Q&A

Exhibit No.	Marked for ID	Admitted in Evidence	Description
131			7/9/2004 Final HHE of Limb Fractures of Recovery Filter
132			7/12/2004 MAUDE data re comparative filters
133			7/13/2004 Email from Mukherjee to DeCant: FW Rationale for purchasing SEM
134			7/13/2004 Email re RAP expansion of vena cava during thrombosis beyond IVC filter
135			7/13/2004 Recovery Filter Migration RAP, SPA 04-05-01
136			7/15/2004 Email regarding review & comment on for Management Board Meeting on 7-23-04
137			7/19/2004 Confidential Product Audit of Bard Recovery Filter System - Glen Falls Operation; cover page
138			7/19/2004 Confidential Product Audit of Bard Recovery Filter System agenda
139			7/20/2004 Handwritten notes re sales growth and failure of Recovery
140			7/22/2004 FW: Management Review Report; Email sending files for the Q2 Mgt Board Review
141			7/22/2004 PPT Management review topics, status updates for Q1 and Q2 2004
142			7/23/2004 Altran Preliminary SEM
143			7/24/2004 Limb fractures of the Recovery
144			7/26/2004 Email string from Chanduszko to vonLinden re SEM
145			8/1/2004 Recovery IFU related to permanent filter
146			8/2/2004 Email between Janet Hudnall and John Kaufman
147			Withdrawn - 8/2/2004 Email re analysis of nitinol filters
148			8/2/2004 Recovery Filter migration failure investigation reported on 7/29/2004
149			8/4/2004 Email re filter fracture action items

Exhibit No.	Marked for ID	Admitted in Evidence	Description
150			8/5/2004 Notes from Sales Call with Dr. Speed, attendees Hudnall, Graves and Williamson
151			8/11/2004 Fault Tree Analysis re: Recovery arm fracture
152			8/13/2004 Updated Fault Tree
153			8/18/2004 Email regarding SPA 04-05-01 comments
154			8/20/2004 Email regarding Fracture Remedial Action Plan Schedule (Draft, 8-17-2004)
155			8/23/2004 Emails regarding filter fracture updates
156			8/27/2004 HHE by Ciavarella re apparent migration of Recovery
157			8/27/2004 Limb Fractures of the Recovery Filter; Computer Aided Engineering Peter Barrett PE
158			8/31/2004 Avijit Mukherjee memo re Recovery filter arm fracture investigation
159			9/1/2004 Email string from vonLinden to Chunko re Recovery filter arm fracture investigation
160			9/1/2004 Failure analysis of 11 complaint, draft technical report 11-0245-00-TR-001, Altran
161			9/1/2004 FIR Recovery Filter - Fractures FIR-01-09-01
162			9/1/2004 MAUDE data re comparative filters, Executive Summary with Weiland and Ring
163			9/7/2004 MAUDE data re comparative filters
164			9/9/2004 Email re attached RAPs and action items
165			Duplicate - See Ex 1208 - 9/10/2004 Email chain re: Dear Doctor Letter revisions
166			9/13/2004 Emails between Robert Lerdahl and Brad Hubbard naming Kaufman and Venbrux for animal use proposal

Exhibit No.	Marked for ID	Admitted in Evidence	Description
167			9/16/2004 Email between Janet Hudnall and John Kaufman
168			9/17/2004 Email from Hudnall email with Venbrux comments re Dear Doctor letter
169			9/27/2004 Email to Tim Ring and John Weiland re IVC MAUDE database summary thru Q2 2004
170			9/29/2004 Email between Janet Hudnall and John Kaufman
171			10/1/2004 Comparative filter sales and MAUDE
172			10/5/2004 Email re Bard Recovery filter system RF-048F, K031328
173			10/8/2004 MAUDE data re comparative filters
174			10/10/2004 Email between Janet Hudnall and John Kaufman
175			10/12/2004 Recovery filter migration failure investigation reported on August 23, 2004
176			10/26/2004 Quality Assurance Quarterly Management Board Review, graphs of summary of complaints for the 3rd Quarter of 2004
177			11/1/2004 Email from Hudnall re filter questionnaire
178			11/2/2004 Pathology co-development relationship
179			11/3/2004 Migration of Recovery Filter
180			11/4/2004 Email with FIR and SPA re labeling changes
181			11/9/2004 AER chart all filters 2000-2004
182			11/10/2004 Email from Ford to Hudnall, IVC filter complications Q&A
183			11/17/2004 HHE re Update Limb Fractures; Updated HHE re Limb Fractures of Recovery Filter
184			11/18/2004 Email between Janet Hudnall and John Kaufman
185			11/28/2004 Email to Tim Ring and John Weiland; FDA suggested changes to IFU and Dear Doctor letter for RF

Exhibit No.	Marked for ID	Admitted in Evidence	Description
186			11/30/2004 Email re: RNF communication plan; Discusses customer communication script to be approved by corporate including Q & A section. Includes PowerPoint training program discussion. Ending dear doctor letters with IFUs same day as US webcast planned for 12/6/2004.
187			12/1/2004 Complaint Record Detail Report-MDR Investigation for event occurring on 10/26/04
188			12/1/2004 Email between Janet Hudnall and John Kaufman
189			12/1/2004 FIR re Migrations; FIR-04-12-01 Rev. 00
190			12/1/2004 Quality Assurance summary December 2004 compliance audits
191			12/1/2004 Recovery IFU 12/04
192			12/7/2004 RAP, SPA-04-04-01; 32 reports of RNF limb detachment
193			12/9/2004 MAUDE data re comparative filters
194			12/13/2004 Fax re FDA 510(k) notification letter related to RF-048F
195			12/14/2004 Draft press release Q&A
196			Duplicate - See Ex 1032 - 12/17/2004 HHE summarizing Lehman Report
197			12/21/2004 Hudnall's sales forecast Recovery, 2006 sales budget, excel chart with an overview of all Recovery Filter product complaints, and filter sales top 100 by city, state, and hospital.
198			12/27/2004 Email between Janet Hudnall and John Kaufman
199			12/31/2004 Comparative MAUDE rates
200			2005 and 2010 Work Order for Parts and Checklists
201			2005 - June 2005, Research Consent Form, Everest Study, Dr. Christoph Binkert

Exhibit No.	Marked for ID	Admitted in Evidence	Description
202			2005 - May 2005, Consent Form for Participation in Research Study, Everest Study, Dr. Haraldur Bjarnason, Mayo IRB Consent Form Template
203			1/4/2005 Email from Zwald to other employees at Glenn Falls
204			1/7/2005 Bard RNF Filter Finite Element Analysis update, attached to above email.
205			1/7/2005 Email from Chanduszeko to Carr re FEA update
206			1/11/2005 Recovery Filter Migration RAP SPA-04-12-01 Amendment 1
207			1/12/2005 Draft Dear Doctor Letter and Recovery Customer Survey Draft from 1/12/2005
208			1/14/2005 Draft Dear Colleague letter regarding Recovery migrations in bariatric patients
209			1/14/2005 Email with attachments from Hudson to Carr re G1A fast Track test Plan
210			1/21/2005 Email from Ganser to Ring regarding RF action plan status
211			1/21/2005 Memo to board of directors, update on RF status
212			1/23/2006 Hershey Medical Center, Consent Form, Everest Study, Dr. Frank Lynch, IRB protocol 22322
213			1/24/2005 Phase 0 Design Review G1A Recovery Filter Femoral Delivery System
214			1/25/2005 Email from Carr to Mukherjee re Proposed Recovery G1A Fast Track Test Plan
215			1/25/2005 Meeting Minutes touching on R&D and Recovery Filter
216			1/26/2005 Email from Carr to Mukherjee re Proposed Recovery G1A Fast Track Test Plan, follow-up
217			2/1/2005 Email from Peter Palermo to Ramon Ricart, Mary Mayo, Uelmen, and Len DiLorenzo, February 2005 QA meeting agenda

Exhibit No.	Marked for ID	Admitted in Evidence	Description
218			2/4/2005 Recovery Filter Detached Limbs-Patient Comparison Matrix
219			2/7/2005 Email Ganser to Ring re RF Action Plan Status and Migration-Detachment summary
220			2/7/2005 Executive Summary regarding MAUDE data re comparative filters
221			2/7/2005 G1A Design Verification and Validation Protocol
222			2/7/2005 Recovery: Post-Market Registry
223			2/11/2005 Attachment B: Bariatric Surgeon Survey
224			2/11/2005 Non-Linear Stress Analysis, Summary Report - RNF Original and Modified Filter
225			2/12/2005 Attachment F: Summary of Expert Panel Meeting; Summary of Bariatric Surgeon Expert Panel Meeting from 2/12/2005
226			2/12/2005 Bard Round Table Discussion New Orleans 2/12/2005, transcript
227			2/12/2005 Summary of Bariatric Surgeon Expert Panel Meeting
228			2/13/2005 Email between Janet Hudnall and John Kaufman
229			2/15/2005 Email re Filter Complications-MAUDE
230			2/16/2005 FEA;FEA
231			2/16/2005 Recovery Filter G1A Femoral system;G1A recovery filter design failure mode and effects analysis. For jugular/subclavian delivery system see DFMEA 070021
232			2/17/2005 Recovery Filter Subject Product Analysis: Migration SPA-04-12-01 Addendum 1
233			2/22/2005 Phase II Design Review G1A Recovery Filter Femoral Delivery System
234			2/23/2005 Interim Clinical Evaluator Report; LyChron Interim Clinical Evaluator Report
235			2/24/2005 Email between Janet Hudnall and John Kaufman

Exhibit No.	Marked for ID	Admitted in Evidence	Description
236			2/24/2005 LyChron Study Interim Report
237			3/1/2005 Email between Janet Hudnall and John Kaufman
238			3/1/2005 Recovery Filter Design Enhancements, PPT
239			3/2/2005 Email between Janet Hudnall and John Kaufman
240			3/15/2005 Executive Summary, MAUDE data re comparative filters
241			3/15/2005 Executive Summary, MAUDE data re comparative filters
242			3/16/2005 Email from Carr to Chanduszkore Altran proposal
243			3/16/2005 Email from Walcott to Carr re Altran proposal
244			3/18/2005 G2 traditional 510(k) summary
245			3/22/2005 G1A product performance specification
246			3/24/2005 Email Ciavarella forwarded the Recovery Post-Market Registry to Rich Holcomb
247			3/24/2005 Migration Resistance Evaluation of "New England Precision Grinding" G1A Manufactured Filters (RF210F)
248			3/24/2005 Outline of FDA meeting agenda
249			3/28/2005 Recovery Filter Dear Colleague Letter, update on internal analysis of Recovery
250			3/29/2005 Email between Janet Hudnall and John Kaufman
251			3/30/2005 Faxed Letter from FDA Office of Device Evaluation to Karen Hutchinson
252			3/31/2005 G1A special 510(k) FDA letter
253			4/1/2005 Complaint failure analysis draft letter, Altran to Frank Madia
254			4/1/2005 G2 Filter IFU
255			4/3/2005 Email between Janet Hudnall and John Kaufman
256			4/4/2005 Complaint Record Detail Report - MDR Investigation for event occurring 1/21/2005

Exhibit No.	Marked for ID	Admitted in Evidence	Description
257			4/5/2005 Email Fridline to Chanduszkore modified filter
258			4/5/2005 ETR 05-02-11 REV 1; Engineering Test Report Number, Chronic Animal Study Report
259			4/6/2005 Email corporate and divisional leadership meeting on April 6, 2005
260			4/8/2005 FM0332100; ETR-05-03-02 with approval form
261			4/10/2005 Email between Janet Hudnall and John Kaufman
262			4/15/2005 Complaint Record Detail Report, MDR Investigation of migration on 3/23/2005
263			4/19/2005 Email re Q&A for physicians at Royal Columbian Hospital
264			4/19/2005 Executive Summary, MAUDE data re comparative filters
265			4/20/2005 Recovery response to FDA request for additional information
266			4/20/2005 Recovery response to FDA request for additional information
267			4/25/2005 Email to Hutchinson and Carr re use of filters in morbidly obese patient population
268			4/26/2005 Summary of call with FDA's Dave Buckles
269			5/2/2005 Informed Consent Guidelines for Clinical Research, Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital, Statement of Volunteer Informed Consent for Research, Everest Study, Dr. William Rilling, Milwaukee, WI
270			5/5/2005 Email re Caval narrowing
271			5/9/2005 Altran Proposal to Perform Corrosion Testing
272			5/9/2005 Email: re Recovery submission strategy; email Berry to Ganser: FDA want traditional 510(k) and a small clinical trial before approving retrievability

Exhibit No.	Marked for ID	Admitted in Evidence	Description
273			Duplicate - See Ex 1645 - 5/9/2005 Memo: Monthly Global PV Report - April 2005
274			5/11/2005 FDA meeting Dear Doctor letter with list of places sent on 6/9/2005 and email sent 5/25/2005
275			5/25/2005 Email with G1A Recovery DV&V Report attached (project 8027) showing change from SNF to RNF
276			5/26/2005 Complaint Record Detail Report -MDR Investigation 03/29/2005
277			5/31/2005 Email Chanduszko to Carr regarding FEA, wants to use Recovery in software demo
278			6/3/2005 Letter from Shari Allen to Angela Smith (Office of Device Evaluation), Special 510(k) filed for the Recovery System
279			6/7/2005 Altran Report; Altran failure Analysis of RNF
280			6/16/2005 Executive Summary; MAUDE data re comparative filters (Migrations/Fractures)
281			6/23/2005 Authorization for Market Release, G1A Recovery Filter Femoral System
282			6/25/2005 Email between Janet Hudnall and John Kaufman
283			6/27/2005 Maude and filter sales Q2 2005
284			7/08/2005 Recovery Investigational Device Exemption (IDE) Application
285			7/8/2005 Email Allen email to Bliss re Dear Doctor IFU and Bariatric Adverse Event letter
286			7/8/2005 FDA response to IDE application
287			7/18/2005 Bob Scherer to Hudnall re MGH request for IRB study
288			7/19/2005 Complaint Record Detail Report - MDR Investigation for complaint on 6/6/2005

Exhibit No.	Marked for ID	Admitted in Evidence	Description
289			8/1/2005 US Launch of the G2 Filter System, IFU G2 8/05
290			8/03/2005 Email From Janet Sullivan to Charis Campbell Re: EVEREST MEDICAL MONITOR
291			8/3/2005 Informed Consent Form for Everest Study, Stravropoulos
292			8/05/2005 Email From John Kaufman to Charis Campbell Re: Dr. Kandarpas cv EVEREST Medical Monitor
293			8/8/2005 Email re FDA letter granting conditional approval for Recovery
294			8/9/2005 Lay Summary and Informed Consent, Everest Study, Dr. Frederick Rogers
295			8/11/2005 Consent and Authorization Form, Everest Study, Kaufman
296			8/14/2005 Email from Wedlock to Ciavarella: telecon with Harper and Gibbs
297			8/15/2005 Memo AER Chart, executive summary
298			8/17/2005 email RE: Recovery Filter Dear Colleague letter; Email chain discusses the appropriate distribution of the Dear Colleague Letter in all geographies
299			8/25/2005 Bard RNF Filter Arm Analysis Preliminary Finite Element Results; Bard RNF Filter Arm Analysis Preliminary Finite Element Results
300			8/25/2005 FDA conference call meeting minutes re Recovery Filter System IDE (G050134)
301			8/26/2005 Email from McDermott to Kellee Jones re Limb Detachment Report
302			8/26/2005 Email with org chart
303			8/31/2005 US Launch of the G2 Filter System RF-310F
304			9/1/2005 IFU G2 9/05
305			9/2/2005 G2 FAQs

Exhibit No.	Marked for ID	Admitted in Evidence	Description
306			9/6/2005 Informed Consent, University of Florida, Everest Study, Dr. James Caridi
307			9/6/2005 Clinical Study Protocol, Everest Study, BPV-RC-1332
308			9/7/2005 Authorization for Market Release, G2 Filter System - Femoral Delivery Kit
309			9/13/2005 Email from Kellee Jones to Chris Ganser sending him updated attachments on RNF migrations and fractures; Email sending updated spreadsheets on RNF migrations and fractures without attachments
310			9/13/2005 Executive Summary re MAUDE data re comparative filters
311			9/14/2005 Informed Consent Form, Everest Study, IRB#090513, Dr. Anthony Venbrux
312			09/15/2005 Email From Charis Campbell to Janet Hudnall Re: Medical Monitor
313			09/15/2005 Email From Charis Campbell to Janet Hudnall Re: Medical Monitor
314			09/15/2005 Email From Charis Campbell to Lauren Baker re: Medical Monitor Follow Up
315			9/19/2005 BPV Division Update ;PPT European Board Meeting 9/20/2005
316			9/22/2005 Fax re: extending distribution of Recovery Nitinol Filter past 8/24/2005 to 9/30/2005;Report extending distribution of Recovery Nitinol Filter until 9/30/2005
317			9/28/2005 Informed Consent Form, Everest Study, IRB#090513, Dr. Anthony Venbrux
318			9/28/2005 Email re: IDE Submissions Update; "the decision to go forward with electropolishing has been made"
319			10/4/2005 Complaint Record Detail Report - MDR Investigation for complaint on 8/9/2005

Exhibit No.	Marked for ID	Admitted in Evidence	Description
320			Withdrawn - 10/5/2005 Re: Bard Recovery Filter Problems, Abington Memorial Hospital
321			10/17/2005 Email Madia to Chanduszko, Baskerville, and Wong re SNF
322			10/20/2005 Email Farair to Chanduszko about what to discuss at a later phone meeting; email Farari to Chanduszko about what to discuss at a later phone meeting
323			10/20/2005 Hudnall Marketing Manager - IVC Filters
324			10/21/2005 Email McBrine to Chanduszko: RE: tip analysis
325			10/24/2005 Research Subject Information and Consent Form, BPV-RC-1332, WIRB protocol 20051917, Dr. Drooz, Inova Research Center, Olympia, WA
326			10/24/2005 Proposal to Perform Metallurgical Assessments of VC Filter Tips Wire Welds
327			10/26/2005 Diagram of filter hook with dimensions; Diagram of filter hook with dimensions
328			10/26/2005 Email Chanduszko to McKrell RE: update proposal for 6 devices; email Chanduszko to McKrell RE: update proposal for 6 devices
329			10/26/2005 email Spilka to Chanduszko RE: surface area
330			10/28/2005 Proposal to Perform Metallurgical Assessments of VC Filter Tip to Wire Laser Welds
331			10/31/2005 Email Chanduszko to Quach RE: SNF HAZ Test Method; email Chanduszko to Quach RE: SNF HAZ Test Method
332			10/31/2005 Email Greenburg to Sanford: Filter Wire process capability
333			11/2/2005 G1A Recovery Filter System Chronic Animal Study Report; ETR 05-02-11 Rev 0 G1A Recovery Filter System Chronic Animal Study Report (Project# 8027)

Exhibit No.	Marked for ID	Admitted in Evidence	Description
334			11/4/2005 Email Chanduszko to Peck
335			11/4/2005 Email Klocke to Ferari about pusher wire "bowing" in some filters
336			11/4/2005 Email Klocke to Gallagher: Jigs; email Klocke to Gallagher: Jigs
337			11/4/2005 Jig dimension data; attachment to above email: Jig dimension data
338			11/8/2005 Attachment to above email: G2 Filter Length Measurements
339			11/8/2005 Complaint Record Detail Report - MDR Investigation; Prophylactic Placement of recovery filter for gastric bypass
340			11/8/2005 Email Lapid to Chanduszko and Graves: Filter Length Results
341			11/9/2005 samples for surface chemical testing
342			11/11/2005 email re: New Adverse Incident Involving Recovery Filter
343			11/11/2005 Email with BNI Animal-Bench Study 11/9/2005
344			01/07/2006 Letter from Krishna Kandarpa Re: Response to IRB Question Bard EVEREST Clinical Study - Medical Monitor Oversight
345			2/17/2006 Recovery Filter G1 Product Assessment Team Minutes-Fractures
346			2/27/2006 Addendum to BPV Remedial Action Plan SPA 04-04-01
347			4/3/2006 Email to Brian Hudson re updated Recovery Filter chronology, R002chronology_3 31 06.doc
348			4/17/2006 Email between Janet Hudnall and John Kaufman
349			4/28/2006 RA-STD-0002 (Rev. 10);Regulatory Affairs Manual
350			5/16/2006 Consent to Participate in Study, Cleveland Clinic Foundation, Everest Study

Exhibit No.	Marked for ID	Admitted in Evidence	Description
351			6/9/2006 PPT: Phase One Optional IVC Filter Request for Approval to Negotiate; PPT regarding proposed benefits of acquiring anchor technology for IVC Filters.
352			7/27/2006 FIR-06-01-01G2 Filter, opened in 1/2006 regarding caudal migration.
353			9/8/2006 Failure Investigation Report G2 Filter, Femoral Delivery System; Tight Spline Project #8048 "Crossed Legs" FIR-06-08-02
354		9-26-18	9/19/2006 PPT re G2; Caudal Movement causes tilting which leads to perforation PPT last modified 3/16/2009 (custodian Mike Randall)
355			9/26/2006 Bard, 7 years of consistent service PLUS
356			10/2/2006 Draft SPA for RNF Fracture; Draft RAP re Filter Fractures
357			10/16/2006 WJH Engineering FEA
358			10/19/2006 G2 Filter Presentation; Presentation notes for Charleston Area Medical Center
359			11/13/2006 Addendum to WJH Engineering Report
360			12/1/2006 G2 Tip Fracture
361			12/22/2006 Email from Darlene Lieske to Bob Obrien
362			1/15/2007 RA-STD-0002 (Rev. 11); Regulatory Affairs Manual
363			01/25/2007 Note to File - EVEREST Re: call to Krishna Kandarpa regarding patient 06/009
364			2/9/2007 Re: Documents Signed Out; Email to Kristy Gephart re bringing lab books
365			2/20/2007 Email with AER Chart for G2
366			3/16/2007 Email and PPT re Project Saturn, Anchor Technology
367			3/19/2007 R A Projects; Project start and close dates

Exhibit No.	Marked for ID	Admitted in Evidence	Description
368			3/20/2007 E-mail re AER Chart Type A and B for Recovery fracture complaint trends, 12/2003 thru 1/2007.
369			3/21/2007 Maude data through Q1 2006; email with attachment re AER Q1 2006 and comparative filters
370			04/11/2007 Email From John Lehmann to David Ciavarella Re: MedMon and AEs Films
371			4/16/2007 Comparison of Nonsymmetrical Loading on the G2 Filter Device in Two Orientations Using FEA; WJH Engineering FEA on the G2
372			05/07/2007 Bard EVEREST Medical Monitor Adjudication Meeting Minutes
373			05/10/2007 Minutes from Deborah Kinsman Re: Disparity in IVC abnormalities and Penetration
374			05/11/2007 Email From David Ciavarella to Elizabeth Rutter Re: Everest Medical Monitor Meeting
375			05/11/2007 Email From David Ciavarella to Michelle Michela re: EVEREST Table 17 Abnormal IVC Appearance
376			05/14/2007 Email From Michelle Michela to David Ciavarella Re: Update on Medical Monitor meeting discussions
377			05/17/2007 Email From John Lehmann to Michelle Michela Re: Update on Medical Monitor Meeting Discussions
378			05/21/2007 Email From John Lehmann to Michelle Michela Re: Indications and Thromboembolic disease listing
379			05/22/2007 Email From John Lehmann to Michelle Michela Re: Indications and Thromboembolic Disease Listing
380			5/22/2007 FEA G2 Tilted; WJH Engineering FEA G2 Tilted
381			6/7/2007 Everest Study Investigator List, with Investigators and IRB name and address

Exhibit No.	Marked for ID	Admitted in Evidence	Description
382			6/11/2007 Email - Sec 8.3.3 Relative Filter Movement; Series of E-mails between Lehmann, Reviere, Van Vleet, Salzman, and others, discussing Everest final study report versions A through H.
383			6/11/2007 Everest IDE Annual Report
384			06/18/2007 Email From Michela Michelle to John Lehmann Re: Inconsistent Migration
385			06/19/2007 Email From John Lehmann to Michela Michelle Re: Primary Endpoint Error?? What about 04-005
386			06/19/2007 Email From Michelle Michela to John Lehmann Re: Primary Endpoint Error? What about 04-005
387			06/19/2007 Email From Michelle Michela to John Lehmann Re: Primary Endpoint Error? What about 04-005
388			06/19/2007 Email From Michelle Michela to John Lehmann Re: Primary Endpoint Error? What about 04-005
389			06/20/2007 Email From John Lehmann to Michela Michelle Re: Primary Endpoint Error?? What about 04-005
390			06/25/2007 Email From John Lehmann to Michela Michelle Re: Filter Penetration of Bowel Wall
391			06/26/2007 Email From Elizabeth Rutter to Michelle Michela Re: Don't forget new analysis for Section 7.4.2
392			06/28/2007 Email From John Lehmann to David Ciavarella Re: Patient 11-003
393			06/28/2007 Email From Elizabeth Rutter to Janet Hudnall Re: EVEREST FSR rev B
394			06/28/2007 Email From Elizabeth Rutter to Janet Hudnall Re: EVEREST FSR rev B
395			06/28/2007 Email From John Lehmann to David Ciavarella Re: Patient 11-003
396			06/28/2007 Email From John Lehmann to Lauren Baker Re: Patient 11-003
397			06/28/2007 Email From Stephanie Klocke to Mike Casanova Re: EVEREST FSR rev B

Exhibit No.	Marked for ID	Admitted in Evidence	Description
398			06/28/2007 Email From Elizabeth Rutter to Janet Hudnall Re: EVEREST FSR rev B
399			06/28/2007 Email From Elizabeth Rutter to Janet Hudnall Re: EVEREST FSR rev B
400			06/28/2007 Email From John Lehmann to Lauren Baker Re: Patient 11-003
401			07/06/2007 Email From Janet Hudnall to Robert Carr Re: EVEREST FSR rev B
402			07/09/2007 Email From Brian Hudson to Gin Schulz Re: Natalie's Filters Update
403			07/09/2007 Email From Michela Michelle to John Lehmann Re: Additional issue re migration
404			07/09/2007 Email From Natalie Wong to Brian Hudson Re: Natalie's Filters Update
405			07/09/2007 BBA Note to File Memo: - Dr. Kandarpa response to call from Bard re: patient 06-010
406			07/09/2007 BBA Note to File Memo: - Transcription of Phone Message from John VanVleet to Dr. Lauren Baker on 07/06/07 regarding patient 06-010
407			07/24/2007 Email From John VanVleet to John DeFord Re: Issues with BBA - EVEREST FSR Data Review
408			7/25/2007 Email Randall to Rabine attaching all FEA engineering reports
409			07/26/2007 Email From John DeFord to John VanVleet Re: Kris Kandarpa
410			07/26/2007 Email From John DeFord to John VanVleet Re: Kris Kandarpa
411			07/26/2007 Email From John Van Vleet to John DeFord Re: Kris Kandarpa
412			7/27/2007 RA-STD-002 (Rev 12);Regulatory Affairs Manual
413			07/31/2007 Email From John DeFord to Krishna Kandarpa Re: EVEREST Discussion
414			08/02/2007 Email From John DeFord to Krishna Kandarpa Re: EVEREST Discussion
415			08/06/2007 Email From John Deford to Krishna Kandarpa Re: EVEREST Discussion

Exhibit No.	Marked for ID	Admitted in Evidence	Description
416			08/06/2007 Email From John Van Vleet to John DeFord Re: EVEREST Discussion
417			08/31/2007 Email From John VanVleet to John Reviere Re: Schedule BBA calls
418			9/5/2007 Tetra Project #8049: Concept Design Review, PPT
419			9/23/2007 EVEREST Response #3 Panel Meeting; attachment is PDF about the Expert Panel that was convened in June 2006.
420			9/27/2007 email from Bill Cleary to docro@mindspring.com (Dr. Ro) re MAUDE JVIR
421			10/17/2007 Email and G3 Fatigue and Corrosion Testing;G3 Fatigue and Corrosion Testing
422			10/24/2007 Email re Recovery G2 Filter Study (Everest) Final Study Report, TD-00456, between 12/7/2005 and 7/24/2006, Protocol BPV-RC- 1332, IDE G050134
423			11/30/2007 BPV R&D Monthly Report
424			12/5/2007 G2 Animal Study
425			1/1/2008 G2 Express Special 510(k)
426			1/1/2008 IFU G2 2008
427			1/9/2008 G3 brainstorming, ppt
428			2/21/2008 FEA by WJH Engineering
429			2/22/2008 Email with attached draft G2 Express Flat Plate and Corrosion Test
430			2/23/2008 Email with attached revised G2 Express Flat Plate and Corrosion Test
431			4/7/2008 Email and AER Chart re G2 Filter complaint data from March 2007 to March 2008
432			4/17/2008 GMP Training PPT revised, GMP Training
433			4/23/2008 Email Filter Franchise review meeting
434			5/14/2008 re TM of the Month - February; sales advice letter
435			6/30/2008 RA-STD-002 (Rev 13);Regulatory Affairs Manual

Exhibit No.	Marked for ID	Admitted in Evidence	Description
436			7/2/2008 Correspondence from FDA re: 510(k) G2 Express; Letter from FDA
437			8/7/2008 Email Perry to Randall re FEA
438			8/25/2008 Saint Luke's Conference call-complaint on fracture
439			8/29/2008 RA-STD-002 (Rev 14);RA-STD-002(Rev 14)
440			9/16/2008 C.R.Bard Work Order/Lot History
441			11/10/2008 FW: Nov Filter Franchise Meeting; email with attached Filter Complaint Rates
442			11/30/2008 Email re G2 Fracture Report Update G2 Fracture Analysis, PPTs from 7/1/2005 thru 11/30/2008
443		9-19-19	11/30/2008 G2 and G2X Fracture Analysis Reporting date range 7/1/2005 thru 11/30/2008
444			12/1/2008 Month-end hospital backorder report - detail - November 30th 2008;email from Luytens: backorder report as of 11/30/2008
445			2/23/2009 Bard Denali PPT
446			3/1/2009 IFU G2 03/09
447			4/1/2009 Filter - Fracture Analysis (June 2010)
448			4/23/2009 G2 Platinum POA concept
449			4/29/2009 BARD PICC study; Bard PICC study: likelihood of meeting the SAFE PICC study endpoints.
450			5/5/2009 BPV Radiology Inventory, Email and Complaint Chart with Complaints from 2004 - 2009
451			5/06/2009 - Perforation Test-competitive filter test results, cover email and excel sheet with results
452			5/14/2009 Bard IVC Filters Program May 2009; Mike Randall PPT re G2 Platinum explains dynamics of vena cava
453			6/12/2009 G2 Fracture Complaint and Manufacturing Review
454			7/1/2009 IFU G2 7/09;IFU adds tilt and caudal migration

Exhibit No.	Marked for ID	Admitted in Evidence	Description
455			7/10/2009 G2 IVC Filter Design Changes
456			7/30/2009 Filter Response Update
457			8/31/2009 Email with BPV Marketing Monthly Report August 2009 attached
458			9/1/2009 Email and e News - 15Sept09 Bard G2; Story for G2 on 2 recent JVIR studies
459			9/23/2009 Denali Idea POA, Sign Off Sheet
460			10/1/2009 IFU - G2
461			11/19/2009 Q&A for Fractures of a Nitinol IVC Filter, discusses Nicholson study
462			11/20/2009 FMEA Eclipse REV 1; FMEA Eclipse Rev 1
463			12/2/2009 FW: 8/20 and 8/21 meeting minutes; email and attachments re IFU
464			12/3/2009 TP and TMs Denali; Email from Angela Crall to Joseph Blessan re various tests
465			12/16/2009 Caudal Push Force; Caudal Push Force Test for the G2
466			12/21/2009 Email and Denali DFMEA final REV 0 Concept Phase; DFMEA Denali final Rev 0 Concept phase:
467			1/4/2010 Email AER Chart from Gin Schulz to John DeFord, Bill Altonaga with attached MAUDE from Jan 2000 to Nov 2009
468			1/6/2010 Bard Questions 1-5-10; Recovery/G2 complaint rates
469			1/13/2010 Email from Cheryl Farbod to Tony Siciliano re Time Change Staff Meeting
470			1/14/2010 Eclipse Filter Product Performance Specifications and Risk Analysis
471			1/21/2010 Caudal Push Test; Email with attached test results from Angela Crall to Chanduszeko re Caudal Push Test
472			1/26/2010 FW: interesting articles; Articles from Lynch re Distention of vena cava

Exhibit No.	Marked for ID	Admitted in Evidence	Description
473			2/2/2010 Email with attachments of 6 draft TDs. TDs include: TD-01008 rev 2 (PE), TD-00876 rev 3 (Twisting), TD-01007 rev 2 (Malposition), TD-00852 rev 5 (Perforation), TD-00883 rev 5 (Fracture), and Td-00882 rev 4 (Migration).
474			2/4/2010 Denali Design Input Summary Report
475			2/24/2010 Filter FDA Inspection Preparation
476			2/27/2010 PPT by Carr and Baird re IVC filter market
477			3/10/2010 Email string ending from Hudson to Altonaga re Patient Codes
478			3/10/2010 Filter Franchise Review, Denali POA Concept
479			5/18/2010 Email re: Clinical Evaluator Report with attachment; email attaching Dr. Lynch's report
480			5/20/2010 Eclipse Filter System - Femoral and Jugular/Subclavian Delivery Kits Special 510(k) Submission
481			6/25/2010 Email with Preliminary Clinical Severity Matrix
482			6/30/2010 Meridian DFMEA070084 Feasability Rev 0 06302010 GS JC DFMEA penetration perf.
483			7/2/2010 Meridian Claims
484			8/20/2010 Email to Brian Boyle re Caudal Migration comparison chart
485			8/31/2010 Corporate Draft Document for Review and Comment CQA-STD-57
486			1/18/2011 Meridian DHF Binder 2;Meridian DHF Binder 2
487			1/18/2011 Meridian DHF Binder 4;Meridian DHF Binder 4
488			1/18/2011 Meridian DHF Binder 5;Meridian DHF Binder 5
489			1/24/2011 Supplier Activity Inquiry
490			4/13/2011 Quality Management Board Review 4/13/11;Power Point
491			3/29/2012 Email re Meridian

Exhibit No.	Marked for ID	Admitted in Evidence	Description
492			8/29/2012 Recovery and G2 IFUs
493			12/18/2012 Email and PPT and Excel Comparison Charts; Denali New Product Training, Design comparisons with the G2 and G2X
494			11/1/2013 Letter of Agreement between IVC Filter Study Group Foundation and Bard Peripheral Vascular
495			3/26/2015 Recovery Filter System; Recovery Filter Overview
496			10/22/2008 Email title: EVEREST information with attachments
497			Altran SEM Examination; Discussion of SEM examination of the surfaces of three selected arm wires
498			Attachment D: Summary of RNF Customer Survey ;Summary of Bard Recovery Filter Customer Survey
499			BARD Adjudication Manual of Operations EVEREST
500			Bariatric Surgeon Panel power point of meeting summary
501			BPV Recover Filter Failure Investigation Remedial Action Plan; Blank Cover Page
502			Comparative filter Migration Resistance Summary
503			Dear Doctor draft with changelog
504		9-25-18	Eclipse Concept POA
505			Fatalities and Complications per Unit Sold; Fatalities and Complications per Unit Sold, compares with other filters
506			Fatalities and rates of different filters
507			G2 Filter System- Femoral and Jugular/Subclavian Delivery Kit 510(k)
508			G2 Fracture Analysis Apr 09;G2 Fracture Analysis April 2009
509			Duplicate - See Def Ex 5387 - G2 IFU 00/00
510			G2 IFU Femoral Vein Approach
511			G2 Retrievable Vena Cava Filter, PPT

Exhibit No.	Marked for ID	Admitted in Evidence	Description
512			IFU update, Recovery: Dear Doctor letter 18months after availability
513			Informed Consent Form, Upenn Research Subject, not dated, Everest Study, Dr. Stavropoulos
514			Jon Conaway "Bard Filter Franchise Team Homework (April 2)"
515			Percentage of Sales by Specialty; Top 5 Recovery Accounts
516			Perforation Test, 18mm IVC, Bard Testing Celest, etc. Comparison of G2 and SNF
517			PowerPoint, "Device Overview" of Recovery G2 Filter and Everest Study, By John Kaufman
518			Q2 2004 NP Sales Run Rates; Q2 2004 NP Sales Run Rates
519			Recovery Filter Commercialization Strategy; Presentation
520			Recovery Filter Fault Tree Analysis
521			Recovery Filter System - Regulatory Strategy Flowchart
522			Response to Maude Data Review; PAT evaluation
523			Sales Growth Memo
524			Sample Consent Form, Everest Study
525			Summary of Bariatric Surgeon Survey
526			Summary of Customer Survey; Summary of Customer Survey - most frequent problem is tilt
527			Allen Deposition, 10/09/2013, Exhibit 01 - Plaintiff Kevin Phillip's Notice of Deposition of Shari Allen and RFP
528			Allen Deposition, 10/09/2013, Exhibit 02 - Curriculum Vitae of Shari Allen O'Quinn

Exhibit No.	Marked for ID	Admitted in Evidence	Description
529			Allen Deposition, 10/09/2013, Exhibit 03 - Vena Cava Filter Overview (Glen Falls), detailing NMT's timeline with the modified version of the SNF in the form of the Recovery filter, with handwritten notes that the FDA was "worried about migration...fracture...[and] cava puncture".
530			Allen Deposition, 10/09/2013, Exhibit 05 - 11/27/2002 FDA Letter re. Clearance for Bard Recovery Filter System, K022236, with 510(k) Summary of Safety and Effectiveness Information
531			Allen Deposition, 10/09/2013, Exhibit 07 - 7/25/2003 FDA Letter re. Clearance for Bard Recovery Filter System, K031328, with 510(k) Summary of Safety and Effectiveness Information
532			Allen Deposition, 10/09/2013, Exhibit 08 - 8/29/2005 FDA Letter re. Clearance for Bard Recovery Filter System, K050558, with 510(k) Summary of Safety and Effectiveness Information
533			Allen Deposition, 10/09/2013, Exhibit 09 - 3/28/2003 Document RE. "Product Opportunity Appraisal for Recovery Filter", FM070018, Doc No. POA-7081, Version 000
534			Allen Deposition, 11/02/2010, Exhibit 01 - PowerPoint presentation re. Recovery Filter generation timeline, U.S. sales, testing, and complications; and an overview of the Superior Delivery System, incl. objective, prototype, and milestones
535			Allen Deposition, 11/02/2010, Exhibit 02 - Recovery Filter Arm Fracture, Remedial Action Plan SPA-04-04-01 Dated 9/2/2004, including RAP SPA-04-08-01, BPV's Patient Comparison Matrix and Fault Tree Analysis, and Dr. Ciavarella's HHE

Exhibit No.	Marked for ID	Admitted in Evidence	Description
536			Allen Deposition, 11/02/2010, Exhibit 03 - BPV's Business Proposal for The Trauma Center at The Regional Medical Center at Memphis, with bullet points of BPV's plans to gain the filter business at RMC
537			Allen Deposition, 11/02/2010, Exhibit 04 - IDE Application for the Bard Recovery Filter System (G050134), including FDA letters re. Bard's deficiencies and Bard's supplements to the application, correcting the deficiencies.
538			Allen Deposition, 11/02/2010, Exhibit 05 - 6/3-6/8/2005 E-mail exchange b/w McDermott and Shari Allen Re. "Recovery Filter System - Fast Track G1A" - Received the license to market the Recovery G1A in Canada
539			Allen Deposition, 11/02/2010, Exhibit 06 - 9/14/2006 E-mail from DeLeon Re. "Reimbursement Information" recently shared with John McDermott, attaching a chart entitled "Common Peripheral Vascular Procedures and Estimated Payment Rates", with a reminder that this cannot be shared with customers.
540			Allen Deposition, 11/02/2010, Exhibit 07 - Bard Chart Entitled "Category Codes for Bard Products"
541			Allen Deposition, 11/02/2010, Exhibit 09 - 1/14/2005 E-mail exchanges b/w Hudnall and Allen re. "updated FDA script and customer letter", exchanging comments and drafts of the revised Recovery documents (customer letter and FDA Talking Points). John Weiland is very concerned with last sentence of 1st paragraph, as it has the potential to increase litigation risk.

Exhibit No.	Marked for ID	Admitted in Evidence	Description
542			Allen Deposition, 11/02/2010, Exhibit 10 - 10/4-10/10/2005 E-mail exchange b/w Hudnall, Walcott, and Carr Re. "Urgent: SNF FRACTURE", with the incident report and photos from the fracture attached (although attachment not included in exhibit). Also included Y. Wakamori of Medicon's contact to Dr. Kaufman directly regarding the fracture incident, with Dr. Kaufman and Wakamori's exchange attached; Hudnall would like to avoid customers such as Medicon contacting Dr. Kaufman directly.
543			Allen Deposition, 11/02/2010, Exhibit 11 - 8/3/2005 E-mail exchange b/w Wedlock and McDermott re. Australian Death, Complaint No. AUS05183. "Very concerning incident, as everything seems to have been according to the IFU" and the physicians were very experienced, highly regarded, and well-trained on Recovery.
544			Altonaga Deposition, 10/22/2013, Exhibit 01 - Plaintiff Kevin Phillip's Notice of Deposition of Bill Altonaga and RFP
545		9-26-18	Altonaga Deposition, 10/22/2013, Exhibit 03 - 2/26-2/27/2004 E-mail exchange b/w Hudnall and David Rauch of BPV Re. "Case for Caval Centering"
546			Altonaga Deposition, 10/22/2013, Exhibit 04, Lehmann Deposition 4/2/13, Ex. 14 and Ferarra, Ex. 7, Barry Deposition, 01/31/2014, Exhibit 18 - 4/13-4/15/2004 E-mail exchange b/w Lee Lynch, Lehmann, and others Re. "Crisis Plan and Supporting Documents for Your Review"
547			Altonaga Deposition, 10/22/2013, Exhibit 05 and Sullivan Deposition, 09/16/2013, Ex. 428 - Recovery Internal Q&A, Version 8/30/2004

Exhibit No.	Marked for ID	Admitted in Evidence	Description
548			Asch Deposition, 01/05/2011, Exhibit 01 - Curriculum Vitae of Dr. Murray Asch, Radiologist
549			Asch Deposition, 01/05/2011, Exhibit 02 - Article by Dr. Murray Asch, entitled "Initial Experience in Humans with a New Retrievable IVC Filter"
550			Asch Deposition, 01/05/2011, Exhibit 03 - 11/13/2002 Live Case Filter Removal, demonstration by Dr. Murray Asch
551			Asch Deposition, 01/05/2011, Exhibit 04 - Grassi, et al. 2003 article entitled "Quality Improvement Guidelines for Percutaneous Permanent IVC Filter Placement for the Prevention of Pulmonary Embolism"
552		9-20-18	Asch Deposition, 05/02/2016 - Exhibit 202 - 5/18/1999 Letter from Thomas Kinst, Product Manager of Filters at NMT Medical, to Monica Coutanche, Marketing Manager at Bard Canada, Inc.
553		9-20-18	Asch Deposition, 05/02/2016 - Exhibit 203 - 9/14/2002 Memo from Thomas Kinst to Recovery Filter Design History File Re. Recovery Filter Compassionate Use, Subject: "Conference call with Bard Peripheral Technologies regarding clinical assessment of Recovery Filter removal #5"
554			Asch Deposition, 05/02/2016 - Exhibit 204 - 1998 article by Millward, entitled "Temporary and Retrievable Inferior Vena Cava Filters: Current Status"
555			Asch Deposition, 05/02/2016 - Exhibit 205 - 2005 article by Asch and Cheung et al., entitled "Temporary inferior vena cava filter use in pregnancy"

Exhibit No.	Marked for ID	Admitted in Evidence	Description
556			Asch Deposition, 05/02/2016 - Exhibit 207 - 1/26/2001 Letter from Mount Sinai Hospital to Dr. Asch Re. "Assessment of a New Temporary/Removable IVC Filter" - and - 11/8/2001 Letter from Mount Sinai Research Ethics Board Re. "MSH Reference #01-0161-U
557			Asch Deposition, 05/02/2016 - Exhibit 208 - 8/28/2000 E-mail from Paul Stagg to Cavagnaro, Mellen, Uelmen, Vierling, and Field Re. "Fwd[2]: compassionate IVC filters (from Asch)",
558			Asch Deposition, 05/02/2016 - Exhibit 209 - Article by Dr. Murray Asch, entitled "Initial Experience in Humans with a New Retrievable IVC Filter"
559			Asch Deposition, 05/02/2016 - Exhibit 210 - 4/17/2002- Email from George Cavagnaro to Doug Uelmen and Carol Vierling, dated April 18, 2002,
560			Asch Deposition, 05/02/2016 - Exhibit 211 - 6/2/2007 E-mail from Monica Coutanche to Janet Hudnall Re. "TM Feedback on the Celect Registry in Canada", forwarding information on the Cook Celect Patient Registry in Canada, in which "They will continue to use the Recovery G2 at about 20% usage".
561		9-2018	Asch Deposition, 05/02/2016 - Exhibit 212 - Special 510(k) Submission for the Recovery Filter System, K022236, dated 11/27/2002
562			Asch Deposition, 05/02/2016 - Exhibit 217 - Spreadsheet entitled "Recovery IFU Notification Tracking"
563		9-2018	Asch Deposition, 05/02/2016 - Exhibit 218 - Information for Use - Recovery Filter System, Dated 2004
564			Asch Deposition, 05/02/2016 - Exhibit 220 - Spreadsheet entitled "Recovery Filter 'Dear Colleague' Letter II Report (May 2005)"

Exhibit No.	Marked for ID	Admitted in Evidence	Description
565			Asch Deposition, 05/02/2016 - Exhibit 221 - Documents with photos of a G2 and a Recovery filter
566			Asch Deposition, 05/02/2016 - Exhibit 222 - December 2010 article by Durack et al., entitled "Perforation of the IVC: Rule Rather Than Expectation After Longer Indwelling Times for the Gunther Tulip and Celect Retrievable Filters"
567		9-20-18	Asch Deposition, 05/02/2016 - Exhibit 223 - 3/10/2003 Letter from Dr. Asch Re support for RF
568			Asch Deposition, 05/02/2016 - Exhibit 224 - 8/22/2006 E-mail from Hudnall to Carr re Dr. Asch's involvement with Cook filters
569			Baird Deposition, 06/09/2016 - Exhibit 299 - LinkedIn Profile for Bret Baird
570			Baird Deposition, 06/09/2016 - Exhibit 300 - 7/13/2007 Memo from Doug Bailey at DBMediaStrategies Inc. (Crisis and Strategic Communications PR) to Bret Baird and Bill Little Re. "Crisis Communications Checklist"~
571		9-24-18	Baird Deposition, 06/09/2016 - Exhibit 301 - PowerPoint Presentation entitled BPV Filter Franchise Review dated 5/6/2008 (colored and 43 pages)
572			Baird Deposition, 06/09/2016 - Exhibit 302 - BPV PowerPoint Presentation entitled "G2X/G2 Express Complaint Review", providing an overview on the G2X and G2 Express hybrid timeline, customer complaints (with graphs), and risk assessment reviews
573			Baird Deposition, 06/09/2016 - Exhibit 303 - 3/30/2016 E-mail from Robert Righi To the Filter Franchise Review Team Re. "Filter Franchise Review Kick-off"

Exhibit No.	Marked for ID	Admitted in Evidence	Description
574			Baird Deposition, 06/09/2016 - Exhibit 304 - A story taken from "Warfighting - Maneuver Warfare in the U.S. Marine Corps", page 74-75, on surfaces and gaps, a concept used by BPV's Filter Franchise Team to help frame their strategy.
575			Baird Deposition, 06/09/2016 - Exhibit 305 - 4/30/2010 E-mail from Bret Baird to Many Re. "Filter Franchise Review Team"
576			Baird Deposition, 06/09/2016 - Exhibit 306 - 8/17-8/31/2010 E-mail thread b/w Bret Baird, Gary Ansel, and John Van Vleet Re. "Follow up regarding VIVA symposium", circulating the Filters and DVT/PE slide deck Ansel pulled together for the VIVA conference symposium for review before sending to corporate, with specific attention to Ansel's final statement of the importance of retrieving the filters
577			Baird Deposition, 06/09/2016 - Exhibit 307 - PowerPoint Presentation entitled "DVT & PE: Preventing death and disability"
578			Baird Deposition, 06/09/2016 - Exhibit 308 - Document entitled "2010 Franchise Review - Filter TM Questionnaire"
579			Baird Deposition, 06/09/2016 - Exhibit 309 - 2003 Article by Grassi et al. entitled "Quality Improvement Guidelines for Percutaneous Permanent Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism"
580			Baird Deposition, 06/09/2016 - Exhibit 310 - Idea POA on the G2 Prophylactic Indication, Project No. 8092 Rev. 1.0, revised 7/25/2008 by Bret Baird
581			Baird Deposition, 06/09/2016 - Exhibit 311 - 4/2/2009 BPV Letter to "Dear Sales Representative"

Exhibit No.	Marked for ID	Admitted in Evidence	Description
582			Baird Deposition, 06/09/2016 - Exhibit 312 - Communications Approval Form Re. "Filter Talking Points Guideline", dated 4/7/2009
583			Baird Deposition, 06/09/2016 - Exhibit 313 - 4/15/2009 BPV Letter to "Dear Sales Representative", attaching an "IVC Filter Talking Points Guideline"
584			Baird Deposition, 06/09/2016 - Exhibit 315 - 2008 SIR by John Kaufman, M.D. entitled "Multicenter Retrieivability Trial of the Recovery G2 Filter" to assess the safety of retrieval of the Recovery G2 filter, Abstract No. 550585
585			Baird Deposition, 06/09/2016 - Exhibit 316 - Internal BPV document entitled "CHUM/EVEREST Clinical Overview"
586			Baird Deposition, 06/09/2016 - Exhibit 317 - BPV Document entitled "Clinical Study Overview: The Bard Recovery G2 Filter Study (EVEREST)", released 2008, GB1277 Rev. 1
587			Baird Deposition, 06/09/2016 - Exhibit 318 - Aug. 2010 Article by Nicholson et al. entitled "Online First: Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters and Clinical Implications Including Cardiac Perforation and Tamponade"
588			Baird Deposition, 06/09/2016 - Exhibit 319 - 11/12/2009 E-mail from Bret Baird to Bill Little, John Van Vleet, and Gin Schulz, with others CCed, Re. "Bard Filter Fractures presentation online"
589			Baird Deposition, 06/09/2016 - Exhibit 320 - ABA Project Agreement with BPV, Inc., dated 11/9/2010
590			Baird Deposition, 06/09/2016 - Exhibit 321 - 11/29-12/1/2010 E-mail exchange b/w Bret Baird and Jimmy Balwit Re. "White Paper, Proof 2"

Exhibit No.	Marked for ID	Admitted in Evidence	Description
591		9-24-18	Baird Deposition, 06/09/2016 - Exhibit 322 - Bard Idea POA on the Denali Filter, Project No. 8108 Rev. 0.0, revised August 2009 by Bret Baird
592		9-24-18	Baird Deposition, 06/09/2016 - Exhibit 325 - 4/28/2010 E-mail from Bret Baird to the Sales Team
593			Baird Deposition, 06/09/2016 - Exhibit 326 - 2011 Article by Caplin et al. entitled "Quality Improvement Guidelines for the Performance of Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism"
594			Baird Deposition, 06/09/2016 - Exhibit 327 - Instructions for Use for the G2 Filter System, Femoral Vein Approach, PK5250500 Rev. 0, dated January 2008
595			Baird Deposition, 06/09/2016 - Exhibit 328 - 2009 Article by Binkert et al. entitled "Technical Success and Safety of Retrieval of the G2 Filter in a Prospective, Multicenter Study", which involved caudal migrations in 12% of cases, tilt in 18%, leg penetration in 26%, and recurrent PE in 2%, but concluded that retrieval of the Recovery G2 was safe and successful in most patients (95%)
596			Barry Deposition, 01/31/2014, Exhibit 01 - Plaintiff Cynthia Jones' Notice of Deposition of Brian Barry and RFP
597			Barry Deposition, 01/31/2014, Exhibit 02 - Curriculum Vitae of Brian Barry, current VP of Corporate Regulatory Affairs
598			Barry Deposition, 01/31/2014, Exhibit 04 - 2/13/2004 Memo from Uelmen to Distribution Re. "Filter Migration Meeting Minutes of 2/12/2004" re. Product Assessment Team meeting on 2/12/2004

Exhibit No.	Marked for ID	Admitted in Evidence	Description
599			Barry Deposition, 01/31/2014, Exhibit 06 - BPV Engineering Test Report - Characterization of Recovery Filter Migration Resistance in Comparison to Competitive Product - Phase 1, ETR-04-03-02, Rev 0. Shows Recovery filter has lowest migration resistance of all devices and does not meet their own minimum acceptance criteria.
600			Barry Deposition, 01/31/2014, Exhibit 08 - 6/10-6/11/2004 E-mail Exchange between Robert Carr and John Deford, others CC'ed, Re. "GEN3 Results"
601			Barry Deposition, 01/31/2014, Exhibit 10 - 2/12/2004 "High" importance E-mail exchange b/w Hudnall and Mary Edwards
602			Barry Deposition, 01/31/2014, Exhibit 13 - PowerPoint presentation from June 2004 BPV/Medicon Strategic Planning Meeting in Tempe, AZ, including charts for U.S. market share, sales performance, and clinical data across all manufacturers in 2004
603			Barry Deposition, 01/31/2014, Exhibit 14 - Grassi, et al. 2003 article entitled "Quality Improvement Guidelines for Percutaneous Permanent IVC Filter Placement for the Prevention of Pulmonary Embolism"
604			Barry Deposition, 01/31/2014, Exhibit 19 - 56-page fax from Paul Kowalczyk to Mary Edwards on 5/11/2004, including 5/10/2004 e-mail exchange Re. Latest Bard Filter Plan and Q&As
605			Barry Deposition, 01/31/2014, Exhibit 27 - Consulting Agreement between C.R. Bard and Lehmann Consulting, dated 6/2/2006; a 5/10/2006 letter from Dr. Lehmann detailing the changes from their last full contract in 2003; and a 12/12/2006 executed letter to renew contract through 12/31/2007

Exhibit No.	Marked for ID	Admitted in Evidence	Description
606			Betensky 02/2017 Expert Report - 11/2007, existing Bard adverse event reports, Sales data were provided by BARD for sales prior to 2003
607			Betensky 02/2017 Expert Report - 11/2009, existing Bard adverse event reports
608			Betensky 02/2017 Expert Report - 2008 Data of adverse event reports
609			Betensky 02/2017 Expert Report - 2009 Data of adverse event reports
610			Betensky 02/2017 Expert Report - 2009 Data of adverse event reports
611			Betensky 02/2017 Expert Report - 2010 and 2011 Data of adverse event reports
612			Betensky 02/2017 Expert Report - 2013 Data of adverse event reports
613			Betensky 02/2017 Expert Report - 7/13/15 FDA Warning Letter re 10/6/14 - 11/25/14 inspection
614		9-20-18	Betensky 02/2017 Expert Report - Adverse event reports and monthly sales totals through May 2011
615			Betensky 02/2017 Expert Report - April 10 Data of adverse event reports
616			Betensky 02/2017 Expert Report - Bard report titled "Recovery Filter Adverse Events (Migrations/Fractures), there are 55 migrations and 76 filter fractures reported.
617			Betensky 02/2017 Expert Report - February 20 Data of adverse event reports
618			Betensky 02/2017 Expert Report - G2 Caudal Migration Failure Investigation, presentation slide, 7/1/05 - 6/30/06
619			Betensky 02/2017 Expert Report - January 10 Data of adverse event reports a
620			Betensky 02/2017 Expert Report - July 10 2010, Data of adverse event reports

Exhibit No.	Marked for ID	Admitted in Evidence	Description
621			Betensky 02/2017 Expert Report - June 10 Data of adverse event reports for SNF events
622			Betensky 02/2017 Expert Report - March 10 Data of adverse event reports
623			Betensky 02/2017 Expert Report - May 20 Data of adverse event reports
624			Betensky 02/2017 Expert Report - Q2'03, existing Bard adverse event reports
625			Betensky 02/2017 Expert Report - Q3'04, existing Bard adverse event reports
626			Betensky 02/2017 Expert Report - Q3'05, existing Bard adverse event reports
627			Betensky Expert Report - QUMAS Change Request Creation, FM1142100, Rev. 3
628			Betensky Expert Report - DFMEA070010, Rev. 0: Design Failure Modes and Effect Analysis for the Recovery Nitinol Filter 10/16/2003
629			Betensky Expert Report - DFMEA070022, Rev. 1: Recovery Filter-Femoral System - Design Failure Mode and Effects Analysis: Recovery Filter G1A Femoral System
630			Betensky Expert Report - DFMEA070022, Rev. 4: Recovery Filter-Femoral System - Design Failure Mode and Effects Analysis: Recovery Filter G1A Femoral System
631		7-20-18	Betensky Expert Report - DFMEA070044, Rev. 3: G2 Express - Design Failure Mode and Effects Analysis
632			Betensky Expert Report - DFMEA070063, Rev. 2: G2 Express - Design Failure Mode and Effects Analysis
633			Betensky Expert Report - DFMEA070031, Rev. 6: G2 - Design Failure Mode and Effects Analysis
634			Withdrawn - Betensky Expert Report - DFMEA070031, Rev. 7: G2 - Design Failure Mode and Effects Analysis

Exhibit No.	Marked for ID	Admitted in Evidence	Description
635		9-20-18	Betensky Expert Report - DFMEA070077, Rev. 1: Eclipse (Vail) Filter System - Design Failure Mode and Effects Analysis
636			Betensky Expert Report - DFMEA070081, Rev. 4: Denali Filter System - Design Failure Mode and Effects Analysis
637			Betensky Expert Report - DFMEA070084, Rev. 0: Meridian (Eclipse Anchors) Filter System - Design Failure Mode and Effects Analysis
638			Betensky Expert Report - Document entitled "DFMEARates,"
639			Betensky Expert Report - Document entitled "Filter Launch Dates,"
640			Betensky Expert Report - Exhibit A, SNF (DFMEA 070042) and Recovery (DFMEA 070010)
641			Betensky Expert Report - Exhibit B, SNF (DFMEA 070042), Recovery (DFMEA 070010). G2 (DMFEA 0070022)
642			Betensky Expert Report - Exhibit C, 10-pt and 5-pt scales
643			Betensky Expert Report - Supplement to Report, dated 03/3/17
644			Betensky Expert Report - SPON0700120, Standard Operating Procedure, FMEA revision 05
645			Betensky Expert Report - SPON0700120, Standard Operating Procedure, FMEA revision 06.
646			Betensky Expert Report - SPON0700120, Standard Operating Procedure, FMEA revision 07
647			Betensky Expert Report - SPON0700120, Standard Operating Procedure, FMEA revision 09
648			Betensky Expert Report - SPON0700120, Standard Operating Procedure, FMEA revision 14
649			Withdrawn - Betensky Expert Report - Internal Bard document evidencing version pf Table 2 used by RNF DMFEA of Rev. 4

Exhibit No.	Marked for ID	Admitted in Evidence	Description
650			Withdrawn - Betensky Expert Report - Internal Bard document with launch dates of all Bard IVC filters
651			Withdrawn - Betensky Expert Report - 5-10pt Scale Conversion chart - SOPN0702100, Rev. 0 Table 2, SOPN0702100, Rev. 104, Table 2 and SOPN0702100, Rev. 5-9, Table 2
652			Betensky Expert Report - SOPN0700120, Rev. 10 Table 2, 6/21/2011 - present
653			Withdrawn - Betensky Expert Report - SOPN0700120, Rev. 07 Table 2
654			Betensky Expert Report - SOPN0700120, Rev. 05 Table 2, 8/30/2005 - 6/21/2011
655			Betensky Expert Report - SOPN0700120, Rev. 01 Table 2, 8/23/2004 - 8/29/2005
656			Betensky Deposition, 06/23/2017 - Exhibit 01 - Notice of Deposition for MDL
657			Betensky Deposition, 06/23/2017 - Exhibit 03 - List of documents potentially reviewed
658			Betensky Deposition, 06/23/2017 - Exhibit 04 - Cases Betensky worked
659			Betensky Deposition, 06/23/2017 - Exhibit 05 - Andreoli, Comparison of Complication Rates Associated with Permanent and Retrievable IVC filters: A review of the MAUDE database, JVIR 2014 SIR Meeting
660			Betensky Deposition, 06/23/2017 - Exhibit 07 - Rebuttal Report to Dr. Feigal's Expert Report
661			Betensky Deposition, 06/23/2017 - Exhibit 08 - Betensky Report Supplemental
662			Betensky Deposition, 06/23/2017 - Exhibit 09 - Rebuttal Report to Dr. Ronald's Expert Report
663			Betensky Deposition, 06/23/2017 - Exhibit 10 - Angel, Systematic Review of the Use of Retrievable IVC Filters, JVIR, 2011

Exhibit No.	Marked for ID	Admitted in Evidence	Description
664			Betensky Deposition, 06/23/2017 - Exhibit 11 - Invoice dated 03/22/17
665			Betensky Deposition, 06/23/2017 - Exhibit 12 - Dr. Bentensky's data sources based on Bard documents
666			Betensky Deposition, 06/23/2017 - Exhibit 15 - SNL/SL Filter Sets, DFMEA
667			Betensky Deposition, 07/26/2016 - Exhibit 01 - Notice of Deposition of Rebecca Betensky, Ph.D.
668			Betensky Deposition, 07/26/2016 - Exhibit 03 - Plaintiff's Response to Defendant's Amended Expert Requests for Production to Plaintiff and Supplemental Response Re. Dr. Muehrcke
669			Betensky Deposition, 07/26/2016 - Exhibit 04 - Spreadsheet of Recovery Filter versus Simon Nitinol Filter Analysis through July 2010
670			Betensky Deposition, 07/26/2016 - Exhibit 05 - Plaintiff's Responses to Expert Interrogatories and Supplemental Answers to Dr. Muehrcke
671			Betensky Deposition, 07/26/2016 - Exhibit 06 - Typewritten Notes made by the witness
672			Booker SOF - Email from Amy Butler to Scott Karch, May 9, 2012
673			Booker SOF - July 28, 2014 letter
674			Booker SOF - MCVI Recovery Filter PowerPoint - 03/11/2005 - RF complication rates, including migration test and arm fatigue results
675			Booker SOF - Product performance Meridian
676			Booker SOF Email from J. Greer to J. Hudnall re monthly report, question re billing Medicare for removal, dated 7/22/2005
677			Booker SOF Filter Fracture Analysis, August 2010, Reporting range 7/1/05 - 8/31/10, G2, G2X, and Eclipse

Exhibit No.	Marked for ID	Admitted in Evidence	Description
678			Boyle, 02/02/2017, Exhibit 829 - E-mail chain first one from Robert Righi to Kevin Boyle, dated 5/3/2013, 3 pages
679			Boyle, 02/02/2017, Exhibit 830 - Bard memorandum to Dave Hemink and others from Jim Beasley, dated September 26, 2013, 5 pages
680			Boyle, 02/02/2017, Exhibit 831 - E-mail chain first one from Mike Randall to Kevin Boyle, dated 4/12/2013, 3 pages
681			Boyle, 02/02/2017, Exhibit 832 - E-mail from Steve Williamson to Kevin Boyle, dated 10/14/2013, 1 page
682			Boyle, 02/02/2017, Exhibit 833 - E-mail chain first one from Mike Randall to Kevin Boyle, dated 11/9/2013, 2 pages
683			Boyle, 02/02/2017, Exhibit 834 - E-mail chain first one from Mike Randall to Kevin Boyle, dated 11/11/2013, 3 pages
684			Boyle, 02/02/2017, Exhibit 835 - E-mail from Mike Randall to Kevin Boyle, dated 1/14/2014, 2 pages
685			Boyle, 02/02/2017, Exhibit 836 - E-mail from Mike Randall to Kevin Boyle, dated 2/5/2014, 1 page
686			Boyle, 02/02/2017, Exhibit 837 - E-mail from Jon Conaway to Kevin Boyle, dated 2/18/2014, 2 pages
687			Boyle, 02/02/2017, Exhibit 838 - E-mail chain first one from Mike Randall to Kevin Boyle, dated 2/27/2014, 3 pages
688			Boyle, 02/02/2017, Exhibit 839 - E-mail chain first one from Mike Randall to Kevin Boyle, dated 4/30/2014, 5 pages
689			Boyle, 02/02/2017, Exhibit 840 - Bard memorandum to Jon Conaway and others from Karen DiClaudio, dated April 30, 2015, 2 pages
690			Boyle, 02/02/2017, Exhibit 841 - E-mail chain first one from Stephanie Klocke to Kevin Boyle, dated 5/1/2015, 2 pages

Exhibit No.	Marked for ID	Admitted in Evidence	Description
691			Boyle, 02/02/2017, Exhibit 842 - E-mail chain first one from John Van Vleet to Steve Williamson, dated 11/5/2015, 6 pages
692			Boyle, 02/02/2017, Exhibit 843 - Bard memorandum to Tim Ring from Steve Williamson, dated October 11th, 2016, 46 pages
693			Boyle, 02/02/2017, Exhibit 844 - E-mail chain first one from Mike Randall to Kevin Boyle, dated 5/4/2015, 3 pages
694			Brauer Deposition, 05/23/2014 - Exhibit 11 - Bard's website page about G2 Filter System, Indicated for Retrieval, printed 5/22/2014
695			Brauer Deposition, 05/23/2014 - Exhibit 13 - 5/13/2008 E-mail from Bill Edwards to wjnichmd2@aol.com Re. "FW: Bard Recovery and G2 IVC Filters"
696		10-2-18	Brauer Deposition, 05/23/2014 - Exhibit 16 - Testimony of Marcia Crosse, Director of Health Care, before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives Re. "Medical Devices - Shortcomings in FDA's Premarket Review, Postmarket Surveillance, and Inspections of Device Manufacturing Establishments", dated 6/18/2009
697			Brauer Deposition, 05/23/2014 - Exhibit 17 - 3/10/2010 E-mail from Gin Schulz to Brian Hudson and Scott Neal Re. "FW: Filter FDA Prep Meeting Minutes"
698			Brauer, 08/02/2017, Exhibit 1029 - Plaintiffs' Second Amended Notice of Videotaped Deposition of Christine Brauer
699			Brauer, 08/02/2017, Exhibit 1031 - Attachment B, List of Materials Reviewed, Christine L. Brauer, Ph.D.
700			Brauer, 08/02/2017, Exhibit 1032 - Invoices to Nelson Mullins from Brauer Device Consultants, LLC

Exhibit No.	Marked for ID	Admitted in Evidence	Description
701			Brauer, 08/02/2017, Exhibit 1033 - Notebook for Deposition, produced by the witness
702			Brauer, 08/02/2017, Exhibit 1034 - Article entitled, "ACR-SIR-SPR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism
703			Brauer, 08/02/2017, Exhibit 1038 - June 20, 2007 EVEREST Listing of Device Observations
704			Brauer, 08/02/2017, Exhibit 1039 - Bard Everest Medical Monitor Adjudication Meeting Minutes, August 28, 2006
705			Brauer, 08/02/2017, Exhibit 1041 - Bard Everest Medical Monitor Adjudication Meeting Minutes, October 26, 2006
706			Brauer, 08/02/2017, Exhibit 1042 - Bard Everest Medical Monitor Adjudication Meeting Minutes, December 8, 2006
707			Brauer, 08/02/2017, Exhibit 1043 - Bard Everest Medical Monitor Adjudication Meeting Minutes, December 20, 2006
708			Brauer, 08/02/2017, Exhibit 1044 - (Exhibit number not used)
709		9-25-18	Brauer, 08/02/2017, Exhibit 1046 - Bard Simon Nitinol Filter, Postmarket Surveillance Study Amendment, August 10, 2014
710			Briant Deposition, 08/12/2016 - Exhibit 02 - Printout of the "G2 Filter System" page on Bard Peripheral Vascular's Website
711			Briant, 07/13/2017, Exhibit 01 - Notice of Deposition
712			Briant, 07/13/2017, Exhibit 02 - Jump drive of files produced
713			Briant, 07/13/2017, Exhibit 03 - Reference list of materials received
714			Briant, 07/13/2017, Exhibit 04 - Binder with produced documents, similar to Briant Ex. 6003

Exhibit No.	Marked for ID	Admitted in Evidence	Description
715			Briant, 07/13/2017, Exhibit 05 - Page from test report for the G2 Express filter, "DV&V Plate Fatigue & Corrosion Examination for G2 Express"
716			Briant, 08/03/2017, Exhibit 6000 - A 28-page photocopy of a report from Exponent/Failure Analysis Associates, entitled, "MDL 15-2641- DCG, Bard IVC Filters Products Liability Litigation - Bellwether Group 1 Case Specific Reports," prepared by Paul Briant, Ph.D., P.E., dated July 2017
717			Briant, 08/03/2017, Exhibit 6001 - A four-page photocopy of a document containing tables and photographs of a G2 IVC filter, the first page headed, "Configuration 3 Loading," and a table entitled, "Comparison of G2 Strain Amplitudes for Two Vertebra Spacings," undated, with no Bates numbers
718			Briant, 08/03/2017, Exhibit 6002 - A one-page photocopy of a table headed, "Bard IVC Filter MDL, Load Configurations," undated, with no bates number
719			Briant, 08/03/2017, Exhibit 6003 - A two-page, double-sided copy of an invoice from Exponent to Taylor Daly of Nelson Mullins, dated July 18, 2017, with detail backup, with no Bates number.
720			Bynon Deposition, 05/17/2016 - Exhibit 247A - Photocopy of Figure 3.14 on page 143 of "Section 3.4 / Mechanical Properties of Materials Under Axial Forces," depicting ductile and brittle fractures
721			Carr Deposition, May 8, 2007 - Exhibit 01 - Information for Use document re Recovery Filter System for use in Vena Cava

Exhibit No.	Marked for ID	Admitted in Evidence	Description
722			Carr Deposition, 03/04/2010 - Exhibit 01 - 11/25/2005 FDA Letter re. Clearance for Bard Recovery Filter System, K052578, with 510(k) Summary of Safety and Effectiveness Information
723			Carr Deposition, 03/04/2010 - Exhibit 02 - Information for Use - G2 Filter System for Permanent Placement, Jugular/Subclavian Vein Approach
724			Carr Deposition, 03/04/2010 - Exhibit 04 - 2/7/2007 Enforcement Report, with Recall of G2 Filter System (RF-320J) and Recovery G2 Filter System (RF-220J, for Canada and Australia only). Recalled because BPV has received 3 complaints involving sheath tip damage.
725			Carr Deposition, 03/08/2016 - Exhibit 181 - Plaintiffs' Notice of Deposition Pursuant to Federal Rule of Civil Procedure 30(b)(6) Re. Corporate Structure
726			Carr Deposition, 03/08/2016 - Exhibit 182 - Charts entitled "C.R. Bard, Inc. Organization Charts", revised every year from December 2005 to December 2015
727			Carr Deposition, 03/08/2016 - Exhibit 183 - Chart indicating the function, location incorporated, products, and comments for all Bard- affiliated companies
728			Carr Deposition, 03/08/2016 - Exhibit 184 - Chart indicating the location incorporated and 10-K year for all Bard-affiliated companies, with highlights
729			Carr Deposition, 03/08/2016 - Exhibit 185 - Chart entitled "Discontinued Business Units", indicating the Bard business unit and year discontinued

Exhibit No.	Marked for ID	Admitted in Evidence	Description
730			Carr Deposition, 04/17/2013 - Exhibit 01 - Class of Plaintiffs' Notice of Taking Rule 30(b)(6) Deposition Duces Tecum in Case No. 12-80951- CIV-ROSENBAUM
731			Carr Deposition, 04/17/2013 - Exhibit 03 - Information for Use - Recovery Filter System, Labeling Issue Date: December 2003
732			Carr Deposition, 04/17/2013 - Exhibit 04 - Instructions for Use - G2 Filter System Timeless Performance, Femoral Vein Approach
733			Carr Deposition, 04/17/2013 - Exhibit 05 - Official Copy of Instructions for Use - G2 Express Filter, Femoral Vein Approach
734			Carr Deposition, 04/17/2013 - Exhibit 06 - FAQs Chart about the Recovery G2, for internal use only
735			Carr Deposition, 04/17/2013 - Exhibit 07 - Bard Idea POA - Eclipse Anchor Filter, caudal migration, Rev 0, 4/1/2010 E-mail exchange b/w Tracy Estrada and Ed Fitzpatrick
736			Carr Deposition, 04/17/2013 - Exhibit 08 - 10/22/2007 E-mail from Genevieve Balutowski to Dennis Salzmann
737		9-26-18	Carr Deposition, 04/17/2013 - Exhibit 09 - 8/22-8/25/2008 E-mail exchange b/w Bret Balrd, Mike Randall, and Natalie Wong Re. "[Redacted] Conference call - complaint on fracture"
738			Carr Deposition, 04/17/2013 - Exhibit 11 - Oh, et al. 2011 article entitled "Removal of Retrievable IVC Filters with Computed Tomography Findings Indicating Tenting or Penetration of the IVC Wall", to examine the feasibility and safety of removing retrievable filters with struts external to the IVC wall on CT imaging

Exhibit No.	Marked for ID	Admitted in Evidence	Description
739			Carr Deposition, 05/08/2007, Exhibit 01 - Information for Use - Recovery Filter System, Labeling Issue Date: December 2003
740			Carr Deposition, 09/14/2012 - Exhibit 16 - Plaintiff Teresa Albrecht and Tracy Hammer's, as Personal Representatives on behalf of the Estate of Buna Mae King, Amended Notice to Take Deposition of Corporate Representative of BPV, Inc.
741			Carr Deposition, 09/14/2012 - Exhibit 17 - Defendant's Responses and Objections to Amended Notice to Take Deposition of Corporate Representative of BPV, Inc.
742			Carr Deposition, 09/14/2012 - Exhibit 18 - Chart entitled "Index of Materials Identified in Defendant's Responses and Objections to Take Deposition of Corporate Representative of BPV, Inc.", indicating Bates Numbers and descriptions for each subject matter request
743			Carr Deposition, 09/14/2012 - Exhibit 19 - C.R. Bard, Inc.'s Work Orders/Lot History and Test Reports from September 2009, with G2X Labels and Instructions for Use
744			Carr Deposition, 09/14/2012 - Exhibit 20 - Instructions for Use - G2X Vena Cava Filter, Jugular/Subclavian Vein Approach
745			Carr Deposition, 09/14/2012 - Exhibit 21 - U.S. Patent No. US 8,133,251 B2 for "Removable Embolus Blood Clot Filter and Filter Delivery Unit", submitted by Ravenscroft et al., dated 3/13/2012

Exhibit No.	Marked for ID	Admitted in Evidence	Description
746			Carr Deposition, 09/14/2012 - Exhibit 22 - Patent Application Publication for U.S. Patent No. US 2011/0257677 A1 for "Removable Embolus Blood Clot Filter", submitted by Carr, Jr. et al., dated 10/20/2011
747			Carr Deposition, 09/14/2012 - Exhibit 23 - Patent Application Publication for U.S. Patent No. US 2010/0318115 A1 for "Tubular Filter", submitted by Chanduszek et al., dated 12/16/2010
748			Withdrawn - Carr Deposition, 09/14/2012 - Exhibit 24 - CD (retained by Ms. Placzek)
749			Carr Deposition, 09/14/2012 - Exhibit 25 - Complaint File No. 250927/RF400J opened on 12/8/2009 for a U.S. case of filter migration to the right ventricle, causing cardiac tamponade.
750			Carr Deposition, 09/14/2012 - Exhibit 26 - Failure Investigation Report for G2 Filter Femoral Delivery System - "Crossed Legs", Tight Spline Project No. 8048, FIR-06-08-02
751			Carr Deposition, 09/14/2012 - Exhibit 27 - Acute Animal Study Report, Project No. 8002, for Recovery Filter Jugular/Subclavian System, ETR-05-03-02, Rev 0
752			Withdrawn - BPV-DEP-00001011
753			Carr Deposition, 10/29/2014 - Exhibit 2 - Plaintiff Leslie Tillman's Notice of Deposition of Person Most Knowledgeable Concerning Sales Brochure for the G2 Filter
754			Carr Deposition, 10/29/2014 - Exhibit 2A - Brochure - G2 Filter System for Permanent Placement
755		10-1-18	Carr Deposition, 10/29/2014 - Exhibit 3A - E-mail exchange b/w Hudnall and others from 3/9-10/4/2005 Re. "Special Accounts Roadshow"

Exhibit No.	Marked for ID	Admitted in Evidence	Description
756			Carr Deposition, 11/05/2013 - Exhibit 01 - PowerPoint slide, "An IVC Filter Must..." prevent recurrent PE, maintain patency over time, be easy to use, and avoid complications
757			Carr Deposition, 11/05/2013 - Exhibit 02 - G3 Vena Cava Filter - Design Input Summary Report, DIS-8049, Rev 001
758			Carr Deposition, 11/05/2013 - Exhibit 04 - Code of Federal Regulations 21CFR807.92, Medical Devices - Premarket Notification Procedures - Content and format of a 510(k) summary
759			Carr Deposition, 11/05/2013 - Exhibit 06 - Code of Federal Regulations 21CFR822.1, Postmarket Surveillance - General Provisions
760			Carr Deposition, 11/05/2013 - Exhibit 07 - NMT Medical's 9/1/2000 R&D Technical Report, No. RD-RPT-128, entitled "Investigation Report of a Migrated Recovery Filter in the Human Use Experience at [Redacted]"; unsigned by Robert Carr, Program Director
761			Carr Deposition, 11/05/2013 - Exhibit 08 - 11/27/2002 FDA Letter re. Clearance for Bard Recovery Filter System, K022236/S2, with 510(k) Summary of Safety and Effectiveness Information
762			Carr Deposition, 11/05/2013 - Exhibit 09 - Title 21-Food and Drugs, Section 352 - Misbranded drugs and devices
763			Carr Deposition, 11/05/2013 - Exhibit 10 - 4/13-4/15/2004 E-mail exchange b/w Lee Lynch, Lehmann, and others Re. "Crisis Plan and Supporting Documents for Your Review"
764			Carr Deposition, 11/05/2013 - Exhibit 14 - 5/27/2004 E-mail b/w Greer, Carr, Hudnall, and Sullivan re. "Bariatric patients and filters"

Exhibit No.	Marked for ID	Admitted in Evidence	Description
765			Carr Deposition, 12/19/2013 - Exhibit 01 - C.R. Bard, Inc.'s Work Orders/Lot History and Test Reports from G2 SYS Femoral - Domes in 7/18/2007, with Manufacturing Inspection Reports
766			Carr Deposition, 12/19/2013 - Exhibit 02 - 3/28/2003 Document RE. "Product Opportunity Appraisal for Recovery Filter", FM070018, Doc No. POA-7081, Version 000
767			Carr Deposition, 12/19/2013 - Exhibit 03 - 7/15/2005 E-mail from Mark Wilson to Chanduszko and Mickey Graves Re: "GFO Oven, Filter Jigs, and Process Qualification" re. an "appropriate chain of command" outline to ensure product is safe and efficacious, which Graves forwarded to Robert Carr as a "plan of attack" to ensure proper qualification of the new oven and jigs.
768			Carr Deposition, 12/19/2013 - Exhibit 04 - FAQs Chart about the Recovery G2
769		9-25-18	Carr Deposition, 12/19/2013 - Exhibit 05 - BPV Meridian Claims Matrix, dated 7/2/2010
770		9-25-18	Carr Deposition, 12/19/2013 - Exhibit 06 - Bard's Denali Concept Product Opportunity Appraisal, POA-8108, Rev. 1.0
771			Carr Deposition, 12/19/2013 - Exhibit 07 - PowerPoint presentation entitled "Filters" by Rob Carr, detailing the Recovery Filter G1A design modifications (specifically arm fatigue life improvement) through pictures and charts, the Jugular Delivery System challenges and milestones, and the Recovery Filter G2 scope and milestones
772			Carr Deposition, 12/19/2013 - Exhibit 08 - G1A Recovery Design Verification & Validation Report, Project 8027, ETR-05-02-05 Rev. 0

Exhibit No.	Marked for ID	Admitted in Evidence	Description
773			Carr Deposition, 12/19/2013 - Exhibit 09 - E-mail exchange b/w Brian Hudson, Christopher Ganser, Brian Barry, and John DeFord, with others CC'ed, from 1/19-1/25/2005 Re. "Proposed Recovery G1A Fast Track Test Plan"
774			Carr Deposition, 12/19/2013 - Exhibit 10 - E-mail exchange b/w Avijit Mukherjee, Len DeCant, Robert Carr, and Dog Uelmen from 1/25/2005
775			Withdrawn - Carr Deposition, 12/19/2013 - Exhibit 11 - not offered
776			Carr Deposition, 12/19/2013 - Exhibit 12 - Draft of BPV's Failure Investigation Report, Recovery Filter - Fractures, FIR-04-09-01 Rev. 1
777			Carr Deposition, 12/19/2013 - Exhibit 13 - Draft of Technical Report 11-0245-00-TR-001, Rev. 0, entitled "Failure Analysis of Eleven Complaint Vena Cava Filters", prepared for C.R. Bard-Glens Falls Manufacturing in September 2004
778			Carr Deposition, 12/19/2013 - Exhibit 14 - Recovery Filter Arm Fracture Fault Tree Analysis
779			Carr Deposition, 12/19/2013 - Exhibit 15 - "High" importance e-mail exchange b/w Don von Linden (Sr. Quality Engineer at Glens Falls) and Altran Corporation
780			Withdrawn - Carr Deposition, 12/19/2013 - Exhibit 16 - not offered
781			Withdrawn - Carr Deposition, 12/19/2013 - Exhibit 17 - not offered
782			Withdrawn - Carr Deposition, 12/19/2013 - Exhibit 18 - Declaration Of Murray Asch, M.D. In Support Of Plaintiffs' Reply To Defendants' Opposition To Plaintiffs' Motion For Class Certification
783			Carr Deposition, 12/19/2014 - Exhibit 01 - NMT Filter Product Line Due Diligence, 9/24/01

Exhibit No.	Marked for ID	Admitted in Evidence	Description
784			Carr Deposition, 12/19/2014 - Exhibit 02 - Notice of 30(b)(6)
785			Carr Deposition, 12/19/2014 - Exhibit 03 - Objections to Notice of 30(b)(6)
786			Carr Deposition, 12/19/2014 - Exhibit 04 - Photo of USB
787			Carr Deposition, 12/19/2014 - Exhibit 05 - NMT Vena Cava Filter Product Line Acquisition Proposal, 07/01/2001
788			Carr Deposition, 12/19/2014 - Exhibit 06 - NMT Special 510(k) application for SNF/Straight line, 11/11/1999
789			Carr Deposition, 12/19/2014 - Exhibit 07 - NMT R&D Technical Report, RD-RDT-102, 08/9/1999, RNF Radial Strength Design Verification
790			Carr Deposition, 12/19/2014 - Exhibit 08 - Recovery Filter FMEA: Implant and Delivery System
791			Carr Deposition, 12/19/2014 - Exhibit 09 - Chart entitled "Design Failure Mode and Effects Analysis" on the Recovery Nitinol Filter, F-8020 (DFMEA)
792			Carr Deposition, 12/19/2014 - Exhibit 10 - Design Review Summary Table, Project #7081 (RNF), 09/19/2002; 12/20/2002 Design Review Assessment Status (Phase I)
793			Carr Deposition, 12/19/2014 - Exhibit 11 - Product Performance Specification Recovery Filter and Femoral Delivery System (PPS70016)
794			Carr Deposition, 12/19/2014 - Exhibit 12 - NMT R&D Technical Report, RD-RDT-088, 08/20/1999, In-vivo testing for RNF for Permanent Use and Early Removal
795			Carr Deposition, 12/19/2014 - Exhibit 13 - RNF Design Review II, Design Verification Study Summaries, including Clot captured, migration resistance (RD-SOP-35-02, RD-RPT-100)

Exhibit No.	Marked for ID	Admitted in Evidence	Description
796			Carr Deposition, 12/19/2014 - Exhibit 14 - RNF Design Animal Verification Study, In-vivo occlusion migration resistance data sheets, Beth Israel Hospital, Animal #511, 11/19/1998
797			Carr Deposition, 12/19/2014 - Exhibit 15 - NMT R&D Technical Report, RD-SOP-050, 11/18/1998, RNF Design Verification, In-vivo occlusion migration resistance and deployment/recovery study
798			Carr Deposition, 12/19/2014 - Exhibit 16 - NMT R&D Technical Report, RD-SOP-035.02, 06/27/1999, RNF Migration Study Design Verification
799			Carr Deposition, 12/19/2014 - Exhibit 17 - NMT R&D Technical Report, RD-RPT-100, 08/05/1999, RNF Migration Study Design Verification
800			Carr Deposition, 12/19/2014 - Exhibit 18 - NMT RNF PDT Meeting Notes re Product Development Team, 01/13/1998
801			Carr Deposition, 12/19/2014 - Exhibit 19 - NMT R&D Technical Report, RD-RPT-120, 06/09/2000, Fatigue Evaluation of RNF
802			Carr Deposition, 12/19/2014 - Exhibit 20 - NMT R&D Technical Report, RD-RPT-128, 09/01/2000, Investigation Report of a Migrated Recovery Filter in the Human Use Experience at Mt. Sinai Hospital
803			Carr Deposition, 12/19/2014 - Exhibit 21 - Email re "Physician Panel Agenda", 6/4/2004
804			Carr, 01/19/2017, Exhibit 643 - LinkedIn Profile of Rob Carr, Vice President of International at Bard Peripheral Vascular

Exhibit No.	Marked for ID	Admitted in Evidence	Description
805			Carr, 01/19/2017, Exhibit 644 - Defendants' Response to Plaintiffs' Third Amended Notice of Deposition Pursuant to Federal Rule of Civil Procedure 30(b)(6) and Related Requests for Production of Documents (Opinion Leaders and Sales)
806			Carr, 01/19/2017, Exhibit 645 - Printout from Bard Website, Guidelines and Ethics - Business Ethics Policy, amended and restated 4/12/2006; printed on 10/19/2010
807			Carr, 01/19/2017, Exhibit 646 - Bard's Labeling, Advertising, and Promotion Policy for the Corporate Regulatory Sciences Policy R-004
808			Carr, 01/19/2017, Exhibit 647 - U.S. Launch Plan for the Recovery Filter System, with the overall strategic objective of attaining the #1 position in the vena cava filter market (35-50% market share)
809			Carr, 01/19/2017, Exhibit 648 - "Launch Tactics" Chart within the U.S. Launch Plan for the Recovery Filter System, detailing the description and estimated cost for each program

Exhibit No.	Marked for ID	Admitted in Evidence	Description
810			Carr, 01/19/2017, Exhibit 649 - 2/24/2003 E-mail from John Timko to Janet Hudnall Re. "Recovery", requesting that bariatric surgeon Dr. James Sapala receive 10 Recovery filters a month starting in April, for placement exclusively as a permanent device, as he "loves Recovery and feels his filter volume will at least double with a retrieval indication". Hudnall could not grant his request at the time, as inventory was limited at this time. On 3/2/2003, Hudnall and Kevin Shifrin exchanged e-mails about using Dr. Sapala in the "early use" experience; didn't think they should include him now, but should include the gastric bypass patient population, as well as trauma, orthopedic surgery, neurosurgery, and pediatric.
811			Carr, 01/19/2017, Exhibit 650 - BPV Sales Rep Template of Bariatric Letter to bariatric surgeons, to familiar them with the recent launch of the Bard Recovery and the 'rapidly accelerating' interest in the Recovery amongst bariatric surgeons
812			Carr, 01/19/2017, Exhibit 651 - 8/12/2003 Letter from Dr. Peeler to "All faculty members in all surgical departments, medicine departments and divisions, orthopedic surgery and neurosurgery" Re. "Temporary Inferior Vena Cava Filters", detailing that they now had an IVC filter that could be retrieved up to 6 months after placement, which dictated a "shift in IVC filter patient selection criteria"

Exhibit No.	Marked for ID	Admitted in Evidence	Description
813			Carr, 01/19/2017, Exhibit 652 - 2/9/2004 E-mail from David Vaught, Territory Manager at BPV, to Dona Fiola, Re. "Mailer", attaching a letter template for bariatric surgeons and for orthopedic surgeons, introducing the Bard Recovery Optional Filter, and a spreadsheet of local bariatric and orthopedic surgeons
814			Carr, 01/19/2017, Exhibit 654 - 5/28/2004 E-mail from David Ciavarella to Brian Barry, Christopher Ganser, and John Weiland Re. "Recovery filter discussion with Dr Misra", relaying his meeting with Sanjay Misra of the Mayo Clinic today about the issues surrounding the Recovery Filter; Dr. Misra had "major concerns" in patients who had the filter placed and then went to surgery or otherwise had events that might increase intra-abdominal pressure or lead to major fluid shifts/inadvertent pulling on the IVC, and recommended creating those conditions in a pig model and reviewing their product design for ways to decrease likelihood of migration. John Weiland relayed on 6/2/2004 that Dr. Misra had told him that bariatric patients have the propensity for large shifts in the vena cava due to the amount of fluid administration they receive and questioned why a "tremendously large number of our migrations rae in obese individuals post-gastric bypass procedures or surgery". McDermott asked the Filter Team to summarize the several discussions had thus far with physicians about bariatric patients for Ciavarella's review.

Exhibit No.	Marked for ID	Admitted in Evidence	Description
815			Carr, 01/19/2017, Exhibit 655 - Folder labeled "Recovery Filter Video Conference, 12/16/2005", including: (1) 1/19/2005 E-mail from Doug Uelmen to Several Re. "Migration SPA Update", providing status of corrective actions; (2) BPV Draft FDA Talking Points, with tracked changes, in anticipation of a 1/18/2005 communication with FDA to provide an update to the revised IFU, customer communication, event comparison chart, etc.; (3) and Draft of "Dear Colleague" letter regarding the Recovery filter, with tracked changes and handwritten edits
816			Carr, 01/19/2017, Exhibit 656 - BPV Agenda for the 3/24 Recovery Filter System Meeting with FDA in Rockville, MD, with handwritten notes; includes (1) draft of "Dear Colleague" letter regarding the Recovery filter, (2) Summary of Bariatric Surgeon Expert Panel Meeting on 2/12/2005 in New Orleans, (3) BPV Summary of Bard Recovery Filter Customer Survey, and (4) BPV Summary of Bariatric Surgeon Survey
817			Carr, 01/19/2017, Exhibit 657 - PowerPoint Presentation entitled "Recovery Filter System", from the 3/24 Recovery Filter System Meeting with FDA in Rockville, MD
818			Carr, 01/19/2017, Exhibit 658 - Chart entitled "G2 Filter - FAQs", with handwritten "Final" notation
819			Carr, 01/19/2017, Exhibit 659 - Chart entitled "General Ledger Supporting Data Report", listing expenses for consulting and physicians training, by physician, from 1/1/2002 to 12/31/2008

Exhibit No.	Marked for ID	Admitted in Evidence	Description
820			Carr, 01/19/2017, Exhibit 660 - Bard Recovery Filter Meeting Minutes from 7/23/2002 meeting, from Rob Carr to Kathy Czelusniak, Mary Edwards, Janet Hudnall, and Doug Uelmen
821			Carr, 01/19/2017, Exhibit 661 - 5/9/2003 Memo from Kevin Shifrin to John McDermott Re. "BPV Marketing Report - April 2003"
822			Carr, 01/19/2017, Exhibit 662 - 6/4-6/11/2004 E-mail exchange between Mark Tinsley, Jason Greer, and Diana Thornton Re. "Memphis Vascular Brochure", addressing issues with the photos and content of the brochure
823			Carr, 01/19/2017, Exhibit 663 - 9/2004 E-mail from Jason Greer to Diana Thornton Re. "Referring physician brochure", requesting that Diana send the final Recovery referring physicians brochure to Janet and Zona for approval by the regulatory department; Diana forwarded same day
824			Carr, 01/19/2017, Exhibit 664 - Brochure entitled "Permanent/Optional Vena Cava Filters - A Referring Physicians Guide", by Memphis Vascular Center in Memphis, TN
825			Carr, 01/19/2017, Exhibit 665 - 8/10/2004 E-mail from Jason Greer to Janet Hudnall, forwarding the 8/9/2004 E-mail exchange with Diana Thornton Re. "Referring physician brochure"; Hudnall had requested to run this final Recovery referring physicians brochure through corporate for regulatory approval
826			Carr, 01/19/2017, Exhibit 666 - Brochure entitled "Permanent/Optional Vena Cava Filters - A Referring Physicians Guide", by Washington Hospital Center in Washington, DC

Exhibit No.	Marked for ID	Admitted in Evidence	Description
827			Carr, 01/19/2017, Exhibit 667 - Brochure entitled "Permanent/Optional Vena Cava Filters - A Referring Physicians Guide", by Methodist Radiology Professional Corporation
828			Carr, 01/19/2017, Exhibit 668 - PowerPoint Presentation from MSIT (MID-South Imaging and Therapeutics), detailing filter placement and management, among other things (in color)
829			Carr, 01/19/2017, Exhibit 669 - PowerPoint Presentation from Montgomery Vascular Surgery, detailing filter placement, management, removal, and follow-up (in color)
830			Carr, 01/19/2017, Exhibit 670 - 4/7/2004 E-mail from Janet Hudnall to Several Re. "Response to DM Reports", detailing the concerns that different individuals had about the IVC filter (i.e. tilted, crossed legs, arms outside cava), with responses to those concerns. Joe DeJohn thanked her for the feedback and DeLeon responded with "I told you this would be a hit".
831			Carr, 01/19/2017, Exhibit 671 - 7/20/2006 Memo from Kevin Shifrin to BPV Management Board Re. "Consolidated List of July Action Items and Strategic Planning Meetings"

Exhibit No.	Marked for ID	Admitted in Evidence	Description
832			Carr, 01/19/2017, Exhibit 672 - 9/8/2006 E-mail from Mark Kumping to Rick Guest, Jack Sullivan, and Jason Greer Re. "MVA", reiterating that "we can not directly support training programs in which Physicians train other physicians on "off-label" uses of our products", so they would instead hire a third party entity to manage these programs and provide direction only by way of suggestion. Request that they "keep 'mum'", so as not to ignite a "panic". On 9/9, Greer responded to Kumping, asking about the courses like "Peeler's hands-on".
833			Carr, 01/19/2017, Exhibit 673 - 10/17/2006 E-mail from Hudnall to David Ciavarella, with Brian Barry and John McDermott, Re. "MS&S Resource - Physicians for G2", listing Dr. Anthony Venbrux and Dr. Thomas Kinney as physicians who agreed to discuss serving as a resource for other physicians looking for help with off-label retrieval cases. Barry replied "thanks!"
834			Carr, 01/19/2017, Exhibit 674 - Document entitled "Bad Acts"
835			Carr, 01/19/2017, Exhibit 675 - BPV PowerPoint entitled "IVC Filters - The Evolution Continues", detailing filter indications, the Simon Nitinol, known filter complications, indications for optional filters, the Recovery and G2 Filter vs. Cook and Cordis filters. Conclusion: Optional filters suitable for most patients; limited role for permanent filters.
836			Carr, 01/19/2017, Exhibit 676 - BPV PowerPoint entitled "IVC Filters", by Bret Baird, Mike Randall, and Rob Carr, detailing market trends, the G2 Express, and the solutions and action plan for the G3 Filter System

Exhibit No.	Marked for ID	Admitted in Evidence	Description
837			Carr, 01/19/2017, Exhibit 677 - 8/17-8/26/2010 E-mail thread b/w Bret Baird, Gary Ansel, and John Van Vleet Re. "Follow up regarding VIVA symposium", circulating the "DVT & PE: Preventing Death and Disability" PowerPoint for the VIVA conference symposium for review before sending to corporate
838			Carr, 01/19/2017, Exhibit 678 - PowerPoint template entitled "Update on IVC Filter Technology", to be filled in with physician name and institution, detailing the indications for an IVC filter and why optional filters
839			Carr, 01/19/2017, Exhibit 679 - 10/29/2004 E-mail from Nancy Baklik to Several Re. "Physician Brochures-Jason Greer", inquiring about sharing the expense of printing 1,000 brochures that Greer put together for a couple of his docs", to give to their referring physician base regarding optional filters
840			Carr, 01/19/2017, Exhibit 680 - PowerPoint Presentation entitled "DVT & PE: Preventing death and disability", by Gary Ansel, M.D., detailing DVT and PE, indications for an IVC filter, case studies, and the Bard Filter Platform
841			Carr, 01/19/2017, Exhibit 681 - PowerPoint Presentation entitled "The Diagnosis and Treatment of Iliofemoral DVT" by Mitchell J. Silver, DO
842			Carr, 01/19/2017, Exhibit 682 - 6/9/2004 E-mails Re. "Filter Placement Billing", where Jason Greer asks for the billing codes used for filter placement; Micki Johnson, R.N. provided 7 applicable codes and Carr joked, "I did not see...I82MUCH - Chronic Buffeting"

Exhibit No.	Marked for ID	Admitted in Evidence	Description
843			Carr, 01/19/2017, Exhibit 683 - 4/8/2005 E-mail from Christopher Guerin to Janet Hudnall, Robert Cart, and Charis Campbell Re. "Recovery Registry Data Set", attaching a document entitled "Bard Recovery Filter System Registry"
844			Carr, 01/19/2017, Exhibit 684 - 3/28/2005 "Dear Colleague" letter from BPV, providing an internal analysis of reported adverse events related to the Recovery filter
845			Carr, 01/19/2017, Exhibit 685- 5/11/2005 "Dear Colleague" letter from BPV, providing an internal analysis of reported adverse events related to the Recovery filter
846			Carr, 01/19/2017, Exhibit 686 - PowerPoint Presentation entitled "Denali Filter Update: 24 Month Clinic Data" by Bill Stavropoulos, M.D.
847			Carr Deposition, November 5, 2013 - Exhibit 04 - Code of Federal Regulation Title 21, Cite 21CFR807.92
848			Carr Deposition, November 5, 2013 - Exhibit 05 - Typewritten documents
849			Duplicate - See Ex 3547 - Carr Deposition, November 5, 2013 - Exhibit 06 - Code of Federal Regulation Title 21, Cite 21CFR822.1
850			Carr Deposition, November 5, 2013 - Exhibit 08 - 510(k) Summary of Safety and Effectiveness Information
851			Withdrawn - Carr Deposition, November 5, 2013 - Exhibit 09 - Title 21 , Section 352 Misbranded drugs and devices
852			Carr Deposition, November 5, 2013 - Exhibit 11 - Memo from Barry to Weiland Re: Competitive Filter Data 5/2/05, with attachment

Exhibit No.	Marked for ID	Admitted in Evidence	Description
853			Carr Deposition, November 5, 2013 - Exhibit 12 - Document titled SWOT objective: Increase Revenue and Capture More Market Share
854			Carr Deposition, November 5, 2013 - Exhibit 15 - 12/12/2004 E-mail from Uelmen to Kellee Jones, attaching 12/9/2004 Remedial Action Plan (Revised) SPA-04-12-01
855			Carr Deposition, November 5, 2013 - Exhibit 16 - Final Report 12-14-2004
856			Carr Deposition, March 18, 2016 - Exhibit 183 - Document headed "Entity," "Where Incorporated," "Function," "Products" "Comments,"
857			Carr Deposition, March 18, 2016 - Exhibit 184 - Document headed "Corporation," "Where Incorporated," "10-K year,"
858			Carr Deposition, March 18, 2016 - Exhibit 185 - Document entitled "Discontinued Business Units"
859			Withdrawn - Carr Deposition, June 6, 2017 - Exhibit 967 - (To be provided by witness.)
860			Chanduszko Deposition, 04/23/2015 - Exhibit 01 - Plaintiff Robin Arnold's Notice of Deposition of Andre Chanduszko
861			Chanduszko Deposition, 04/23/2015 - Exhibit 02 - Test Protocol - Flat Plate Fatigue and Corrosion Examination for the G2 Express Filter, Project No. 8058, TP 07-02-12 Rev. 0
862			Chanduszko Deposition, 04/23/2015 - Exhibit 03 - Feasibility Test Protocol - Flat Plate Fatigue and Corrosion Examination for the G3 Filter, Project No. 8049, TP 07-10-09 Rev. 0
863			Chanduszko Deposition, 04/23/2015 - Exhibit 04 - Flat Plate Fatigue and Corrosion Examination Test Method - Research & Development, TM1141700 Rev. 0

Exhibit No.	Marked for ID	Admitted in Evidence	Description
864			Chanduszko Deposition, 04/23/2015 - Exhibit 05 - 3/4/2008 E-mail from Chanduszko and Abtihal Raji-Kubba Re. "Fatigue Report", attaching "DV&V Flat Plate Fatigue and Corrosion Examination Test Report on the G2 Express Filter (Project No. 8058, TR 07-12-01 Rev. 0), which was signed off and submitted to the Doc Control.
865			Chanduszko Deposition, 04/23/2015 - Exhibit 06 - Test Report - Feasibility Flat Plate Fatigue and Corrosion Examination of the G2 Express Filter, Project No. 8058, TR 07-02-12 Rev. 0
866			Chanduszko Deposition, 04/23/2015 - Exhibit 07 - Test Report - DV&V Flat Plate Fatigue and Corrosion Examination Test Report on the G2 Express Filter, Project No. 8058, TR 07-12-01 Rev. 0
867			Chanduszko Deposition, 04/23/2015 - Exhibit 08 - 2/11/2008 E-mail exchange between Mike Randall, Chanduszko, and Stephanie Locke Re. "Flat Plate Round 2", with "Test Report - DV&V Flat Plate Fatigue and Corrosion Examination Test Report on the G2 Express Filter, Project No. 8058, TR 07-12-01 Rev. 0" returned by Stephanie Klocke with her comments.
868			Chanduszko Deposition, 04/23/2015 - Exhibit 09 - NMT R&D Standard Operating Procedure entitled "Rotating-Beam Corrosion Fatigue Testing of Nitinol Wire", RD-SOP-033; no issue date indicated, may be a draft; signed by Nathaniel Herring, Adrian Ravenscroft, and Jason Harry and dated 9/8/1997
869			Chanduszko Deposition, 04/23/2015 - Exhibit 10 - R&D Report entitled "Corrosion Fatigue Testing of NiTi 0.012" Wire at 80% of the Yield to Stress-Induced R-Phase", RD-RPT-038

Exhibit No.	Marked for ID	Admitted in Evidence	Description
870			Chanduszko Deposition, 04/23/2015 - Exhibit 11 - 12/8/2006 Test Protocol, Plan, and Report CR Creation Form created by Chanduszko Re. Rotary Beam Fatigue Test of G2 Filter Wire, Project No. 8049, FM0332100 Rev. 4
871			Chanduszko Deposition, 04/23/2015 - Exhibit 12 - Rotary Beam Fatigue Test of G2 Filter Wire, Project No. 8049, TPR-06-05-17 Rev. 0
872			Chanduszko Deposition, 04/23/2015 - Exhibit 13 - Rotary Beam Fatigue Test of G2 Filter Wire, Project No. 8049, TPR-06-12-04 Rev. 0
873			Chanduszko Deposition, 04/23/2015 - Exhibit 14 - NMT R&D Standard Operating Procedure entitled "EnduraTEC Corrosion/Fatigue Testing of RNF Filters. Design Verification.", issued 6/28/1999, RD-SOP-054.00; signed off by Chanduszko (R&D Engineer) and Adrian Ravenscroft (RNF Sr. R&D Engineer) on 6/28/1999 and Alex Chaharom (Director of QA) on 8/23/1999
874			Chanduszko Deposition, 04/23/2015 - Exhibit 15 - NMT Medical's 8/4/1999 R&D Technical Report, No. RD-RPT-099, entitled "EnduraTEC Corrosion/Fatigue Testing of RNF Filters. Design Verification", by Hernan Lauber (Junior R&D Engineer) and signed off by Chanduszko (R&D Engineer) and Adrian Ravenscroft (RNF Sr. R&D Engineer) on 8/13/1999 and Alex Chaharom (Director of QA) on 8/23/1999
875			Chanduszko Deposition, 04/23/2015 - Exhibit 16 - Health Hazard Evaluation Memo from Ciavarella to Uelmen Re. "Recovery Filter - Consultant's report", dated 12/17/2004
876		9-20-18	Chanduszko Deposition, 04/23/2015 - Exhibit 17 - Pages 30-44 of Notebook No. 7013, Project: Recovery Filter Arm Fatigue Testing

Exhibit No.	Marked for ID	Admitted in Evidence	Description
877			Chanduszko Deposition, 04/23/2015 - Exhibit 18 - Bard's Recovery Filter Arm Fatigue Testing - Research and Development, TM1133800 Rev. 0
878			Chanduszko Deposition, 04/23/2015 - Exhibit 19 - Bard's Approval Form for the Recovery Filter Arm Fatigue Test Report (ETR-04-08-04 Rev. 0), FM0332100 Rev. 2, effective 1/10/2005
879			Chanduszko Deposition, 04/23/2015 - Exhibit 20 - Test Protocol - Recovery Filter Arm Fatigue Design Verification and Validation Protocol, Project No. 8027, TPR-05-01-05 Rev. 0
880			Chanduszko Deposition, 04/23/2015 - Exhibit 21 - Test Protocol - G2 Filter, Clot Trapping Efficiency, Project No. 8049, TPR-06-05-02 Rev. 0
881			Chanduszko Deposition, 04/23/2015 - Exhibit 22 - Test Protocol - G2 Filter, Clot Trapping Efficiency, Project No. 8049, TPR-06-05-02 Rev. 0
882			Chanduszko Deposition, 04/23/2015 - Exhibit 23 - May 2009 PowerPoint presentation entitled "Bard IVC Filters Program" by Abtihaal Raji- Kubba and Mike Randall re. processing
883			Chanduszko Deposition, 04/23/2015 - Exhibit 24 - Document entitled "Filter Fracture Analyses"
884			Chanduszko Deposition, 06/21/2013 - Exhibit 01 - Bard's Project Status Report Form for the Recovery Filter G1A, Project No. 8027 initiated 4/8/2004, FM0700160 Rev. 1, Ref No. DOPN0700020.
885			Chanduszko Deposition, 06/21/2013 - Exhibit 02 - Bard's Authorization for Market Release Form for the G1A Recovery Filter Femoral System, Project No. 8027, Item No. RF210F, FM0700220 Rev. 2

Exhibit No.	Marked for ID	Admitted in Evidence	Description
886			Chanduszko Deposition, 06/21/2013 - Exhibit 03 - Project Summary of Recovery Filter G1A, Project Type: Line Extension
887			Chanduszko Deposition, 06/21/2013 - Exhibit 04 - 9/27/2005 BPV Memo from Mickey Graves to Venus & Jupiter Snarable Filter Team Re: Project #8031 Meeting Agenda for 9/27/2005
888			Chanduszko Deposition, 06/21/2013 - Exhibit 05 - 3/16/2005 Letter
889			Chanduszko Deposition, 06/21/2013 - Exhibit 06 - BPV's G1A Recovery Design Verification & Validation Report, Project 8027, ETR-05-02- 05 Rev. 3
890			Chanduszko Deposition, 06/21/2013 - Exhibit 07- 3/2/2005 Design Failure Mode and Effects Analysis for the G1A, Recovery Filter - Femoral System, Doc No. DFMEA070022
891			Chanduszko Deposition, 06/21/2013 - Exhibit 08 - 5/27/2004 E-mail from Greer to Carr, Hudnall, and Sullivan re. "Bariatric patients and filters"
892			Chanduszko Deposition, 06/21/2013 - Exhibit 09 - PowerPoint slide entitled "Risk Management Evaluation"
893			Chanduszko Deposition, 06/21/2013 - Exhibit 10 - PowerPoint slide entitled "Risk Management Evaluation"
894			Chanduszko Deposition, 06/21/2013 - Exhibit 11 - 7/7/2004 E-mail from Robert Carr to Cindi Walcott Re. "Dr. Ciavarella Recovery Filter Questions"
895			Chanduszko Deposition, 10/10/2013 - Exhibit 01 - Hand-drawn diagram
896			Chanduszko Deposition, 10/10/2013 - Exhibit 02 - U.S. Patent No. US 6,258,026 B1 for "Removable Embolus Blood Clot Filter and Filter Delivery Unit", submitted by Ravenscroft et al., dated 7/10/2001

Exhibit No.	Marked for ID	Admitted in Evidence	Description
897			Chanduszko Deposition, 10/10/2013 - Exhibit 03 - 6/23/1998 NMT Memo from Adrian Ravenscroft Re. "Removable Filter Concepts"
898			Chanduszko Deposition, 10/10/2013 - Exhibit 07 - 7/15/2004 E-mail from Hudnall to TPE-Interventional Sales-DG Re. "Vena Cava Filter Complications Q&A"
899			Chanduszko Deposition, 10/10/2013 - Exhibit 12 - BPV Engineering Test Report - Effects of Changes to the Recovery Filter and the Femoral Delivery System on Filter Stresses Based on FEA Analysis, Project No. 8027, ETR-05-02-02, Rev 0
900			Ciavarella Deposition, 03/01/2011 - Exhibit 01 - Draft of Updated Health Hazard Evaluation Memo from Ciavarella to Uelmen, Re: "Limb Fractures of Recovery Filter", dated 7/9/2004.
901			Ciavarella Deposition, 03/01/2011 - Exhibit 03 - 11/17 and 11/29/2004 E-mail exchange b/w Cindi Walcott to David Ciavarella Re. "Q3 MAUDE Update"; Ciavarella wants ACTUAL numbers
902			Ciavarella Deposition, 03/01/2011 - Exhibit 04 - 5/23/2005 E-mail exchange b/w David Ciavarella and Charis Campbell Re. "Recovery Protocol - Important!", with Ciavarella's comments to the 5/21/2005 "Draft Clinical Protocol" for the Bard Recovery Filter Study (EVEREST) attached
903			Ciavarella Deposition, 03/01/2011 - Exhibit 05 - 8/30-9/1/2004 "High" importance E-mail exchange b/w Ciavarella, Ganser, Hudnall, Barry, and Uelmen Re. "Revisions to Recovery Q/A and Key messages"
904			Ciavarella Deposition, 03/01/2011 - Exhibit 06 - 8/18/2005 Letter from Ciavarella, Phone Conference of 8/8 re Bard Recovery Filter

Exhibit No.	Marked for ID	Admitted in Evidence	Description
905			Ciavarella Deposition, 03/01/2011 - Exhibit 07 - 12/20-12/23/2005 E-mail exchange b/w Walcott and Ciavarella Re. "G2 Caudal Migrations"
906			Ciavarella Deposition, 03/01/2011 - Exhibit 09 - 8/23/2004 E-mail from Uelmen to Barry, Ciavarella, Donna Passero, and Pete Palermo Re. "Filter Fracture Updates"
907			Ciavarella Deposition, 03/01/2011 - Exhibit 10 - Updated Health Hazard Evaluation Memo from Ciavarella to Uelmen, Re: "Migration of Recovery Filter", dated 6/30/2004.
908			Ciavarella Deposition, 03/01/2011 - Exhibit 12 - 5/11/2005 "Dear Colleague" letter from BPV re. the Recovery filter system
909			Ciavarella Deposition, 03/01/2011 - Exhibit 13 - 6/29/2004 E-mail exchange b/w Lehmann and Ciavarella Re. "John Lehmann availability"
910			Ciavarella Deposition, 03/01/2011 - Exhibit 14 - 12/6/2005 E-mail from Gin Schulz to David Ciavarella Re. "For your review", with the Addendum to BPV Remedial Action Plan - "Limb Fractures of Recovery Filter" (SPA 04-04-01, Revised 12/1/2005) attached
911			Ciavarella Deposition, 07/29/2014 - Exhibit 01 - Notice of Deposition
912			Ciavarella Deposition, 07/29/2014 - Exhibit 04 - Information for Use for the Recovery Filter System, dated 2003
913			Ciavarella Deposition, 07/29/2014 - Exhibit 05 - 11/17/2004 Updated Health Hazard Evaluation Memo from David Ciavarella, M.D. to Doug Uelmen, Re: "Limb Fractures of Recovery Filter", relaying 32 reports of limb fractures of the Recovery filter, of the 19,537 units sold, between Jan 2002 and 11/1/2004.

Exhibit No.	Marked for ID	Admitted in Evidence	Description
914			Ciavarella Deposition, 07/29/2014 - Exhibit 06 - Draft of Health Hazard Evaluation Memo from Ciavarella to Uelmen Re. "Recovery Filter - Consultant's report", dated 12/13/2004
915			Ciavarella Deposition, 07/29/2014 - Exhibit 09 - 6/10/2004 E-mail exchange b/w Ciavarella and Cindi Walcott Re. "Recovery Filter/Detachments"
916			Withdrawn - Ciavarella Deposition, 07/29/2014 - Exhibit 10 -
917			Ciavarella Deposition, 08/29/2012 - Exhibit 01 - Health Hazard Evaluation Memo from Ciavarella to Uelmen Re. "Recovery Filter - Consultant's report", dated 12/17/2004
918			Ciavarella Deposition, 08/29/2012 - Exhibit 03 - 10/12/2000 Regulatory Affairs Manual, "Product Remedial Actions", RA-STD-002, Rev. 08
919			Ciavarella Deposition, 08/29/2012 - Exhibit 04 - Addendum to BPV Remedial Action Plan - "Limb Fractures of Recovery Filter", SPA 04-04- 01, Revised 12/1/2005
920			Ciavarella Deposition, 08/29/2012 - Exhibit 05 - Draft of the Addendum to BPV Remedial Action Plan - "Limb Fractures of Recovery Filter", SPA 04-04-01, Revised 12/1/2005
921			Withdrawn - Ciavarella Deposition, 11/12/2013 - Exhibit 20 - Curriculum Vitae of Dr. David Ciavarella, VP of Corporate Clinical Affairs at C.R. Bard
922		9-25-18	Ciavarella Deposition, 11/12/2013 - Exhibit 22 - Chart of Sales and Adverse Events for all competitors from Q3/00 through Q2/03, according to the MAUDE database.
923		9-25-18	Ciavarella Deposition, 11/12/2013 - Exhibit 24 - Summary of Sales and Adverse Events for all competitors from 01/00 through Q1/04

Exhibit No.	Marked for ID	Admitted in Evidence	Description
924		9-25-18	Ciavarella Deposition, 11/12/2013 - Exhibit 26 - Chart of Sales and Adverse Events for all competitors from 01/00 through Q1 2006, according to the MAUDE database.
925		9-25-18	Ciavarella Deposition, 11/12/2013 - Exhibit 28 - PowerPoint presentation entitled "Filters Complaint History Data as of 7/31/2007" by Natalie Wong.
926			Ciavarella Deposition, 11/12/2013 - Exhibit 31 - 8/3/2005 Memo from C. Ganser to T. Ring/J. Weiland Re. IVC Recovery Filter Adverse Events (Migrations/Fractures)
927		9-25-18	Ciavarella Deposition, 11/12/2013 - Exhibit 35 - Health Hazard Evaluation Memo from Ciavarella to Uelmen Re. "Recovery Filter - Consultant's report", dated 12/17/2004
928			Ciavarella Deposition, 11/12/2013 - Exhibit 36 - 2/7/2005 E-mail from Janet Hudnall to Chanduszko, Graves, and Mukherjee Re. "End user Eval of G1A & Short Cone"
929			Ciavarella Deposition, 11/12/2013 - Exhibit 37 - 3/10/2004 Memo from Lehmann to Uelmen Re. "Recovery Filter Migration HHE"
930			Ciavarella Deposition, 11/12/2013 - Exhibit 38 - Updated Health Hazard Evaluation Memo from Ciavarella to Uelmen, Re: "Migration of Recovery Filter", dated 6/30/2004.
931		9-25-18	Ciavarella Deposition, 11/12/2013 - Exhibit 39 - Draft of Updated Health Hazard Evaluation Memo from Ciavarella to Uelmen, Re: "Limb Fractures of Recovery Filter", dated 7/9/2004.
932		10-3-18	Ciavarella Deposition, 11/12/2013 - Exhibit 41 - BPV's 5/6/2008 PowerPoint presentation entitled "Filter Franchise Review", including charts of 2007 U.S. Market Share by \$ and U.S. filter sales history

Exhibit No.	Marked for ID	Admitted in Evidence	Description
933			Cohen, 01/25/2017, Exhibit 724 - Plaintiffs' Amended Notice of Videotaped Deposition of Gary Cohen, M.D.
934			Cohen, 01/25/2017, Exhibit 725 - Nitinol Medical Technologies RNF Marketing Minutes
935			Cohen, 01/25/2017, Exhibit 726 - Slide deck, IVC Filter Advisory Group, November 2, 2000
936			Cohen, 01/25/2017, Exhibit 727 - Recovery Filter Workshop Attendee Nomination Form
937			Cohen, 01/25/2017, Exhibit 728 - Undated e-mail to Janet from John
938			Cohen, 01/25/2017, Exhibit 729 - Document, starting "The Recovery IVC filter is the future of caval interruption."
939			Cohen, 01/25/2017, Exhibit 730 - E-mail dated 10/19/03
940			Cohen, 01/25/2017, Exhibit 731 - Letter dated 10/28/03
941			Cohen, 01/25/2017, Exhibit 732 - Letter dated 3/18/04
942			Cohen, 01/25/2017, Exhibit 733 - E-mail dated 2/26/04
943			Cohen, 01/25/2017, Exhibit 734 - Bard, Recovery Filter Workshop Phoenix, Arizona March 24, 2004
944			Cohen, 01/25/2017, Exhibit 735 - Recovery Workshop: March 24, 2004 Morning Session spreadsheet, double-sided
945			Cohen, 01/25/2017, Exhibit 736 - Monthly Report, IVC Filters/Covered Stents, Janet Hudnall, April, 2004
946			Cohen, 01/25/2017, Exhibit 738 - E-mail dated 5/5/04
947			Cohen, 01/25/2017, Exhibit 739 - Memorandum dated May 6, 2004

Exhibit No.	Marked for ID	Admitted in Evidence	Description
948			Cohen, 01/25/2017, Exhibit 740 - Bard Peripheral Vascular Presentation Dinner advertisement
949			Cohen, 01/25/2017, Exhibit 741 - BPV District Manager's 2004 Sales Report May 2004
950			Cohen, 01/25/2017, Exhibit 742 - E-mail string, top one dated 6/21/04
951			Cohen, 01/25/2017, Exhibit 743 - BPV District Manager's 2004 Sales Report May 2004
952			Cohen, 01/25/2017, Exhibit 744 - June 29th Recovery Dinner
953			Cohen, 01/25/2017, Exhibit 745 - E-mail string, top one dated 6/22/04
954			Cohen, 01/25/2017, Exhibit 746 - E-mails dated 7/12/04
955			Cohen, 01/25/2017, Exhibit 747 - E-mail dated 7/24/04
956			Cohen, 01/25/2017, Exhibit 748 - E-mail string, top one dated 8/3/04, from Janet Hudnall
957			Cohen, 01/25/2017, Exhibit 749 - Bard, Recovery Filter Migration Failure Investigation FIR-04-11-03 January 11, 2005
958			Cohen, 01/25/2017, Exhibit 750 - Bard memo dated 10/15/04 Recovery Crisis Communications Plan
959			Cohen, 01/25/2017, Exhibit 751 - Key Filter Customers Date: 10/27/04
960			Cohen, 01/25/2017, Exhibit 752 - E-mail string, top one dated 11/23/04
961			Cohen, 01/25/2017, Exhibit 753 - E-mail string, top one dated 11/23/04
962			Cohen, 01/25/2017, Exhibit 754 - Recovery Filter Migration-Patient comparison Matrix, 11/4/05
963			Cohen, 01/25/2017, Exhibit 755 - Recovery Filter Migration Failure Investigation Report FIR-04-12-0
964			Cohen, 01/25/2017, Exhibit 756 - E-mail dated 12/14/04

Exhibit No.	Marked for ID	Admitted in Evidence	Description
965			Cohen, 01/25/2017, Exhibit 757 - E-mail dated 12/15/04, with attached FDA Filter Information, FDA called Temple to speak with Cohen
966			Cohen, 01/25/2017, Exhibit 759 - E-mail string, top one dated 8/6/08
967			Cohen, 01/25/2017, Exhibit 760 - E-mail string, top one dated 8/1/03
968			Collins Deposition, 10/20/2010 - Exhibit 1 - NMT Meeting Notes from 8/14/2003 meeting b/w Marie Bell, Harvey Collins, Charlie Benwhere, and Carol Felt re. RNF, RC, and SNF plans, with handwritten notes
969			Cortelezzi, 11/11/2016, Exhibit 561 - "LIMITS" PowerPoint Presentation for BPV's 2004 National Sales Meeting
970			Cortelezzi, 11/11/2016, Exhibit 562 - BPV "Guide to Tactical Programs" for the G2 Filter System
971			Cortelezzi, 11/11/2016, Exhibit 563 - 10/27/2005 E-mail from Bob Scherer to his team Re. "G2 Filter Sales Contest", attaching the current standings for the G2 filter contest and reiterating the key issues: reestablishing the G2 as the "go to filter" in each of their territories; regaining lost business and growing business at the expense of Cordis, Cook, and BSC; and finishing the year strong while creating the necessary ramp to be successful in 2006. "This is a critical product franchise where you must be successful. Failing to substantially grow this product is not an option...Finishing in the money should be the goal we are all chasing". DeJohn responded that they needed to "keep the G2 contest front and center".
972			Cortelezzi, 11/11/2016, Exhibit 564 - "Merchant List" from the Premiere Choice Aware website

Exhibit No.	Marked for ID	Admitted in Evidence	Description
973			Cortelezzi, 11/11/2016, Exhibit 565 - 9/8/2005 E-mail from Janet Hudnall to Many Re. "G2 Filter Programs for DMs Only", distributing details of the G2 Filter launch to the management team only (volume discount pricing, DM sales contest, and award levels)
974			Cortelezzi, 11/11/2016, Exhibit 566 - 12/10/2004 E-mail from Marie Swety of Risk Management at Temple University Hospital Re. "FDA Filter Information", forwarding a document she created based on her own investigation of the MAUDE database, specifically pertaining to data received through 9/30/2004 on migrations of the Recovery Filter; forwarded to others, with a message that the trauma service would no longer be using the Bard Recovery filter for their patients; then forwarded to Bard employees, who relayed that "this is not a good situation", as the FDA had now contacted Temple and Dr. Cohen was disappointed that he had not heard from Marketing since this second migration. Doug Uelmen had never before this heard of the FDA contain a physician.
975			Cortelezzi, 11/11/2016, Exhibit 568 - 3/30/2005 E-mail from Bob Cortelezzi to Janet Hudnall Re. "Recovery Visits", listing the physicians to visit regarding the G1A sorted by geographical area
976			Cortelezzi, 11/11/2016, Exhibit 569 - 6/15/2005 E-mail from Bob Cortelezzi to Janet Hudnall and Robert DeLeon, with No Subject, forwarding questions and concerns from Dr. John Ammerman that he did not feel comfortable using the Recovery filter off-label and had complications (fracture/death)

Exhibit No.	Marked for ID	Admitted in Evidence	Description
977			Cortelezzi, 11/11/2016, Exhibit 570 - 6/15/2005 E-mail from John DeLeon to Janet Hudnall and Bob Cortelezzi Re. "Recovery G2 Roll-out", attaching a roll-out plan that identified the tactics they may need to ensure a successful G2 roll-out
978			Cortelezzi, 11/11/2016, Exhibit 571 - 7/18/2005 E-mail from Janet Hudnall to Many Re. Recovery G2 Special Accounts Roadshow", forwarding spreadsheets entitled "Western Region: G1A Recovery 'Discussion' Customer's - PRIORITY ACCOUNTS" and "Western Region: G1A Recovery 'Discussion' Customer's"
979			Cortelezzi, 11/11/2016, Exhibit 572 - 10/24/2007 E-mail from Brian Doherty to Sales Team Re. "September Rankings", detailing the position of the sales members in the National Sales Contest, forwarded by Hudnall to Robert Carr
980			Cortelezzi, 11/11/2016, Exhibit 573 - 2/12/2008 E-mail from Brian Doherty to DeLeon, Sullivan, Cortelezzi, and Wilson, attaching a BPV Memo entitled "Q1/Q2 2008 Sales Contest" detailing the prizes for the 2/1-5/30/2008 contest and discussing a few thoughts about the contest
981			Cortelezzi, 11/11/2016, Exhibit 574 - 4/27/2008 E-mail from Bob Cortelezzi to Sales Team Re. "Sales contest - Through 4/24", detailing the position of the sales members in the National Sales Contest
982			Cortelezzi, 11/11/2016, Exhibit 575 - BPV Region Manager Monthly Report, dated 5/28/2008, detailing total district sales and significant events for filters and other BPV products
983			Cortelezzi, 11/11/2016, Exhibit 576 - Document listing courses at BPV University

Exhibit No.	Marked for ID	Admitted in Evidence	Description
984			Cortelezzi, 11/11/2016, Exhibit 578 - Document entitled "Interventional Product Training - Day 4 Filters" by Janet Hudnall
985			Cortelezzi, 11/11/2016, Exhibit 580 - 11/17/2004 Updated Health Hazard Evaluation Memo from David Ciavarella, M.D. to Doug Uelmen, Re: "Limb Fractures of Recovery Filter", relaying 32 reports of limb fractures of the Recovery filter, of the 19,537 units sold, between Jan 2002 and 11/1/2004.
986			Cortelezzi, 11/11/2016, Exhibit 581 - 1/19/2005 E-mail from Janet Hudnall to Shari Allen, No Subject, with a paragraph detailing that the current Recovery filter migration-related death rate is 0.398% and, although their rates are "well below the Quality Improvement Guideline thresholds, the majority of deaths had been in bariatric patients.
987			Cortelezzi, 11/11/2016, Exhibit 582- Complaint File on 63855/RF310F, opened 11/7/2005, involving caudal migration and wall perforation of a RF310F
988			Cortelezzi, 11/11/2016, Exhibit 583 - Complaint Record Detail Report for Complaint No. 212907, opened 3/2/2009, involving 90 degree tilt and embedment of an RF400F (G2 Express) discovered at time of retrieval
989			Cortelezzi, 11/11/2016, Exhibit 584 - Complaint Record Detail Report for Complaint No. 190913, opened 9/22/008, involving fracture and 45- 60 degree tilt of an RF400F (G2 Express) discovered at time of retrieval
990			Cortelezzi, 11/11/2016, Exhibit 585 - 10/8/2008 Memo from Jim Beasley to Tim Ring Re. "Monthly Management Report"

Exhibit No.	Marked for ID	Admitted in Evidence	Description
991		9-25-18	Cortelezzi, 11/11/2016, Exhibit 586 - 12/23/2005 E-mail from David Ciavarella Re. "G2 Caudal Migrations", forwarded to Brian Barry on 12/27. Worst case consequence of migrations - accompanied in a majority of tilt cases. Would like to now look at G2 complaints.
992		10-2-18	Cortelezzi, 11/11/2016, Exhibit 588 - 7/16/2005 E-mail from Jason Greer to many Re. "Westy's situation...everyone's situation", detailing Bard's need to respond to Cordis' bringing forward the Maude database to physicians and "causing a problem"
993			D'Ayala Deposition, 03/21/2017, Exhibit 01 - D'Ayala' s Curriculum vitae
994			D'Ayala Deposition, 03/21/2017, Exhibit 04 - IFU, G2 Filter System , 10/2006, Rev. 5, PK5100030
995			D'Ayala Deposition, 03/21/2017, Exhibit 05 - Eastern Vascular Society, Concurrent Prophylactic Placement of Inferior Vena Cava Filter In Gastric Bypass and Adjustable Banding Operations in the Bariatric Outcomes Longitudinal Database
996			D'Ayala Deposition, 03/21/2017, Exhibit 06 - NEJM, A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients With Proximal Deep-Vein Thrombosis
997			D'Ayala Deposition, 03/21/2017, Exhibit 07 - AMA, Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters And Clinical Implications Including Cardiac Perforation and Tamponade
998			D'Ayala Deposition, 03/21/2017, Exhibit 08- NY Methodist Records
999			D'Ayala Deposition, 03/21/2017, Exhibit 11 - 12/27/05 E-Mail from David Ciavarella to Brian Barry

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1000			D'Ayala Deposition, 03/21/2017, Exhibit 12 - Fractured Bard Recovery, G2, and G2 Express Inferior Vena Cava Filters: Incidence, Clinical Consequences, and outcomes of Removal Attempts
1001			D'Ayala Deposition, 03/21/2017, Exhibit 13 - Evidence-Based Evaluation of Inferior Vena Cava Filter Complications Based on Filter Type
1002			DeCant Deposition, 05/24/2016 - Exhibit 248 - Minutes from 11/5/2002 Filter Meeting at BPV on the Permanent Recovery 510(k)
1003			DeCant Deposition, 05/24/2016 - Exhibit 249 - Article by Angela C. Smith and Dorothy B. Abel entitled "Regulation of Peripheral Vascular Devices - Current issues in the regulation of IVC filters," published November 2005 in Endovascular Today
1004			DeCant Deposition, 05/24/2016 - Exhibit 250 - 2/5/2003 Bard PowerPoint Presentation entitled "Peripheral Vascular Project Management" by Leonard DeCant, with slides pertaining to the phase and internal/external impact matrix of each BPV project
1005			DeCant Deposition, 05/24/2016 - Exhibit 252 - Kepner Tregoe Document Re. Strategy Session 2 at BPV in Phoenix, AZ on 7/22-7/23/2003
1006		9-21-18	DeCant Deposition, 05/24/2016 - Exhibit 254 - 12/9/2003 Meeting Minutes Memo from Brian Hudson to Len DeCant, Mike Casanova, Robert Carr, and Alex Tessmer Re. "Special Design Review for Recovery (Project #'s 7081 and 8008)"

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1007			DeCant Deposition, 05/24/2016 - Exhibit 255 - 12/17/2003 E-mail from Laurence Grossman to Mary Edwards Re. "Request for research samples of the Bard Recovery Vena Cava Filter" for use in on-going research within the FDA/CDRH labs, forwarded by Edwards to Len DeCant for suggestion on "how to deal with this hot potato"
1008			DeCant Deposition, 05/24/2016 - Exhibit 257 - 2/13/2004 Meeting Minutes Memo from Doug Uelmen Re. "Filter Migration Meeting Minutes of February 12, 2004"
1009			DeCant Deposition, 05/24/2016 - Exhibit 258 - 4/6/2004 Memo from Peter Palermo to Doug Uelmen Re. "Remedial Action Plan - BPV Recovery Nitinol Vena Cava Filter", including the Remedial Action Plan SPA 04-03-01 on the Recovery Filter, dated 3/26/2004
1010			DeCant Deposition, 05/24/2016 - Exhibit 259 - 2/13/2004 E-mail from Mary Edwards Re. "email to sales force", attaching the proposed e-mail communication to the sales force regarding reports of migration and the group's revisions to same via e-mail
1011			DeCant Deposition, 05/24/2016 - Exhibit 260 - Product Assessment Team/Crisis Communications Team Rosters and an outline of the action plans that must take place by this team if the decision is made to recall the Recovery Filter
1012			DeCant Deposition, 05/24/2016 - Exhibit 261 - 3/12/2004 E-mail from Holly Glass to John Lehmann Re. "Recovery Crisis Communications Plan"
1013			DeCant Deposition, 05/24/2016 - Exhibit 263 - 4/16/2004 Memo from Doug Uelmen Re. "Filter Migration Meeting Minutes, April 16, 2004",

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1014			DeCant Deposition, 05/24/2016 - Exhibit 264 - 6/11/2004 Memo from Pete Palermo to Doug Uelmen Re. "Remedial Action Plan - BPV Recovery Filter - Migration"
1015			DeCant Deposition, 05/24/2016 - Exhibit 265 - Health Hazard Evaluation by John Lehmann on the April 2004 Bard Recovery Filter migration and death, forwarded to Doug Uelmen of BPV on 4/27/2004
1016			DeCant Deposition, 05/24/2016 - Exhibit 266 - 4/23/2004 E-mail from John Lehmann to Carr and Uelmen Re. "Draft data set for statistician"
1017			DeCant Deposition, 05/24/2016 - Exhibit 267 - 5/13/2004 E-mail from John Timko to Hudnall with many CC'ed Re. "Recovery IVC Filter Feedback", providing comments on his initial experience with the retrieval of the Recovery filter, sheath, and cone: significant tilt in at least 30% of his cases, which he believed needed to be addressed, although making changes would increase cost; forwarded by McDermott to DeCant same day as "feedback from the field"
1018			DeCant Deposition, 05/24/2016 - Exhibit 268 - 9/27/2004 Memo from Pete Palermo to Doug Uelmen Re. "Remedial Action Plan - BPV Recovery Filter - Migration (SPA-04-05-01) "
1019			DeCant Deposition, 05/24/2016 - Exhibit 269 - 7/26/2004 Email from John McDermott to Len DeCant
1020			DeCant Deposition, 05/24/2016 - Exhibit 271 - 10/12/2004 Failure Investigation Report on the Recovery Filter Migration, FIR-04-10-01
1021			DeCant Deposition, 05/24/2016 - Exhibit 272 - PowerPoint Presentation entitled "BPV/ANGIOMED New Product Development Review Meeting on September 21, 2004"

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1022			DeCant Deposition, 05/24/2016 - Exhibit 274 - Failure Investigation Report on the Recovery Filter Migration, FIR-04-12-01 Rev. 00
1023		9-21-18	DeCant Deposition, 05/24/2016 - Exhibit 275 - Internal Presentation on the G2 Filter System for Permanent Use, detailing the design modifications, features/benefits, and comparison to the Recovery Filter
1024			DeCant Deposition, 05/24/2016 - Exhibit 276 - Draft of the 2/9/2006 Health Hazard Evaluation from David Ciavarella to Gin Schulz, BPV, Re. "G2 Inferior Vena Cava Filter - Migration", detailing 10 reports of migration of the G2 filter to date
1025			DeCant Deposition, 05/24/2016 - Exhibit 277 - 3/31/2006 Meeting Minutes Memo from S. Allen Re. "G2 Caudal Migration"
1026			DeCant Deposition, 05/24/2016 - Exhibit 278 - 10/22/2007 E-mail from Genevieve Balutowski to Dennis Salzmann
1027			DeCant Deposition, 05/24/2016 - Exhibit 279 - 3/31/2006 E-mail from Cindi Walcott
1028			DeCant Deposition, 05/24/2016 - Exhibit 280 - 6/27/2006 E-mail from Pete Palermo to Gin Schulz and Christopher Ganser
1029			DeCant Deposition, 05/24/2016 - Exhibit 281 - Pathology Report and Photos from the 2/27/2004 removal of Sample #CMP12339
1030			Deford Deposition, 06/02/2016 - Exhibit 282 - Curriculum Vitae For John Andrew DeFord
1031			Deford Deposition, 06/02/2016 - Exhibit 283 - BPV File on The Recovery Filter Migration, including Minutes from the 2/12/2004 Migration Meeting

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1032			Deford Deposition, 06/02/2016 - Exhibit 287 - 12/17/2004 Health Hazard Evaluation from David Ciavarella to Doug Uelmen Re. "Recovery Filter - Consultant's Report",
1033			Deford Deposition, 06/02/2016 - Exhibit 289 - Handwritten Notes on concerns about the HHE and design issues
1034			Deford Deposition, 06/02/2016 - Exhibit 292 - 9/13/2004 Letter from Gen3 Partners to Len DeCant of C.R. Bard, detailing their completion of the Airlock Project and Gen 3's presentation of 32 concepts to reduce filter complications
1035			Deford Deposition, 06/02/2016 - Exhibit 295 - July 2006 Saturn Phase Gate document entitled "Phase One - Optional IVC Filter, Request for Approval to Negotiate", sponsored by BPV
1036		9-25-18	Deford Deposition, 06/02/2016 - Exhibit 296 - 9/26-9/27/2007 High Importance E-mail exchange b/w Dennis Salzmann, John Van Vleet, and John Reviere of BPV, with others CCedd, Re. "Comments on Rev H". Discussion about concern for over-reporting of the SIR guidelines re-classification and removal of the retroperitoneal bleed, and replacing consultant John Lehmann
1037			Deford Deposition, 06/02/2016 - Exhibit 297 - "Fractures of a Nitinol IVC Filter" presentation by Dr. W. Jay Nicholson on www.CRToonline.org, in which he reviewed a single center experience on fractures with the Bard Recovery and G2 filters
1038			Deford Deposition, 06/02/2016 - Exhibit 298 - 8/25/2010 E-mail from John DeFord to Weiland, Schermerhorn, and Beasley Re. "Filters, the FDA and the Cleveland Clinic"

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1039			DeJohn Deposition, 06/17/2016 - Exhibit 335 - 9/25/2005 E-mail exchange b/w Joe DeJohn and John Worland Re. "Ethical Standards"
1040			DeJohn Deposition, 06/17/2016 - Exhibit 336 - Chart entitled "U.S. Launch Proposal - Recovery Vena Cava Filter", detailing the strategic impact, estimated cost, and estimated sales impact of various programs (IVC Filter Advisory Council, User Training Workshops, Market Expansion, Live Cases)
1041			DeJohn Deposition, 06/17/2016 - Exhibit 337 - 9/28/2003 E-mail from Dan Orms to Joe DeJohn Re. "Dr. Venbrux Recovery Presentation"
1042			Dimmit, 01/26/2017, Exhibit 1 - Notice of Deposition
1043			Dimmit, 01/26/2017, Exhibit 2 - Form 10-K for C.R. Bard, Inc. for the fiscal year ended December 31st, 2015
1044			Dimmit, 01/26/2017, Exhibit 3 - Bard's Net Worth (2015)
1045			Dimmit, 01/26/2017, Exhibit 4 - September 30, 2016 Bard Form 10-Q
1046			Dimmit, 01/26/2017, Exhibit 5 - Bard 2015 Annual Report
1047			Dimmit, 01/26/2017, Exhibit 6 - Securities and Exchange Commission Schedule 14A, Proxy Statement
1048			Dimmit, 01/26/2017, Exhibit 7 - C.R. Bard, Inc./Policy Manual
1049			Dimmit, 01/26/2017, Exhibit 8 - December 2015 C.R. Bard - Management P&L
1050			Dimmit, 01/26/2017, Exhibit 9 - Bard - Trademark Details
1051			Dimmit, 01/26/2017, Exhibit 11 - Filter sales by state
1052			Edwards Deposition, 01/20/2014 - Exhibit 01 - Recovery Filter Timeline (Glen Falls) from 1999-2002

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1053		9-26-18	Edwards Deposition, 01/20/2014 - Exhibit 02 - 3/28/2003 Document RE. "Product Opportunity Appraisal for Recovery Filter", FM070018, Doc No. POA-7081, Version 000
1054			Edwards Deposition, 01/20/2014 - Exhibit 03 - 7/25/2003 FDA Letter re. Clearance for Bard Recovery Filter System, K031328, with 510(k) Summary of Safety and Effectiveness Information
1055			Edwards Deposition, 01/20/2014 - Exhibit 05 - Document entitled "2/12/2004 E-mail to Interventional Sales Force", reference in BPVEFILTER-01-00010245 - 246 email. This is the communication sent to the sales force.
1056			Edwards Deposition, 01/20/2014 - Exhibit 06 - 2/12/2004 Voicemail to Interventional Sales Force, provides three options for approach of message to sales force "specific", "in-between", or "general".
1057			Edwards Deposition, 01/20/2014 - Exhibit 07 - Alternate version of 2/12/2004 Voicemail to Interventional Sales Force (to be provided by counsel)
1058			Edwards Deposition, 01/20/2014 - Exhibit 08 - 2/13/2004 Memo from Uelmen to Distribution Re. "Filter Migration Meeting Minutes of 2/12/2004"
1059			Edwards Deposition, 01/20/2014 - Exhibit 09 - 2/19/2004 E-mail from Kellee Jones to many Re. "Update on Recovery Filter Migration & Teleconference 2/20/2004 4:00pm EST", with the "Recovery Filter Migration Update" attached (although attachment not included in exhibit)
1060			Edwards Deposition, 01/20/2014 - Exhibit 10 - BPV Chart entitled "Recovery Filter Migration Update", dated 2/19/2004

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1061			Edwards Deposition, 01/20/2014 - Exhibit 13 - Chart entitled "Recovery Filter Fault Tree Analysis"
1062			Edwards Deposition, 01/20/2014 - Exhibit 14 - BPV PowerPoint presentation entitled "BPV/AngioMed New Product Development Review Meeting - April 26, 2004"
1063			Edwards Deposition, 01/20/2014 - Exhibit 21 - Updated Health Hazard Evaluation Memo from Ciavarella to Uelmen, Re: "Migration of Recovery Filter", dated 6/30/2004.
1064			Edwards Deposition, 01/20/2014 - Exhibit 24 - 9/23/2004 E-mail from Mary Edwards to Uelmen, McDermott, DeCant, DeJohn, and Shifrin Re. "Dear Doctor Letter"
1065			Edwards Deposition, 01/20/2014 - Exhibit 25 - 9/9/2004 E-mail from Mary Edwards to many Re. "Recovery Filter"
1066			Edwards Deposition, 08/19/2016 - Exhibit 357 - 7/10/2002 IMPRA Division's Letter to FDA submitting the Special 510(k): Device Modification application for the Recovery Filter System, detailing the modifications made to the Simon Nitinol filter and delivery system; signed by Kay Fuller and Carol Vierling
1067			Edwards Deposition, 08/19/2016 - Exhibit 359 - "Post-Implant Evaluation" page of the Clinical Experience Section to Dr. Asch's study, detailing that 7 of the 29 patients had thrombus present in the filter in the pre-removal cavagram, 9 showed some change in filter placement when compared to the implant cavogram or experienced some disruption of the caval wall, and 1 showed fracture of the arm and hook

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1068			Edwards Deposition, 08/19/2016 - Exhibit 360 - Product Opportunity Appraisal for the Recovery Filter System, POA-7081 Vers. 0, Released 3/28/2003
1069			Edwards Deposition, 08/19/2016 - Exhibit 361 - 2/13/2004 E-mail to Interventional Sales Force to address entries into the FDA MAUDE database for the Recovery filter
1070			Edwards Deposition, 08/19/2016 - Exhibit 364 - Remedial Action Plan for the Recovery Filter, SPA-04-04-02, dated 4/21/2004
1071			Edwards Deposition, 08/19/2016 - Exhibit 372 - 8/8/2002 E-mail from Susan Alpert to Mary Edwards and Kay Fuller at IMPRA
1072			Edwards Deposition, 08/19/2016 - Exhibit 373 - Attachment E, "Procedural Notes", to the Abbreviated 510(k) for the Recovery Filter System
1073			Edwards Deposition, 08/19/2016 - Exhibit 374 - 11/5/2002 E-mail from Kay Fuller to Carr, with others Cced, Re. "Cool Recovery Movie"
1074			Edwards Deposition, 08/19/2016 - Exhibit 375 - Complaint Record for Complaint No. 5104020023, received on 2/9/2004
1075			Edwards Deposition, 08/19/2016 - Exhibit 376 - Remedial Action Plan for the Recovery Filter Migration, SPA-04-03-01, dated 3/26/2004
1076			Edwards Deposition, 08/19/2016 - Exhibit 377 - Document entitled "Action Items from Recovery Filter Migration Meeting 3/4/2004"
1077			Edwards Deposition, 08/19/2016 - Exhibit 378 - Remedial Action Plan for the Recovery Filter Migration, SPA-04-04-02, dated 4/21/2004

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1078			Edwards Deposition, 08/19/2016 - Exhibit 379 - BPV Document entitled "Recovery Filter Migration Update, February 17, 2004
1079			Edwards Deposition, 08/19/2016 - Exhibit 381 - 11/10/2004 Memo from Lisa Kinnell, Microbiologist, to K031328/A002 for the C.R. Bard Recovery Filter Re. "Summary of file and recommendations"
1080			Exhibit Number Skipped
1081			Exhibit Number Skipped
1082			Exhibit Number Skipped
1083			Exhibit Number Skipped
1084			Exhibit Number Skipped
1085			Exhibit Number Skipped
1086			Exhibit Number Skipped
1087			Exhibit Number Skipped
1088			Exhibit Number Skipped
1089			Exhibit Number Skipped
1090			Exhibit Number Skipped
1091			Exhibit Number Skipped
1092			Exhibit Number Skipped
1093			Exhibit Number Skipped
1094			Exhibit Number Skipped
1095			Exhibit Number Skipped
1096			Exhibit Number Skipped
1097			Exhibit Number Skipped
1098			Exhibit Number Skipped
1099			Exhibit Number Skipped
1100			Exhibit Number Skipped
1101			Exhibit Number Skipped
1102			Exhibit Number Skipped
1103			Exhibit Number Skipped
1104			Exhibit Number Skipped
1105			Exhibit Number Skipped
1106			Exhibit Number Skipped
1107			Exhibit Number Skipped
1108			Exhibit Number Skipped
1109			Exhibit Number Skipped
1110			Exhibit Number Skipped
1111			Exhibit Number Skipped
1112			Exhibit Number Skipped

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1113			Exhibit Number Skipped
1114			Exhibit Number Skipped
1115			Exhibit Number Skipped
1116			Ferrari Deposition, 04/02/2014 - Exhibit 01 - Jennifer Coker's Second Amended Notice of Deposition of Thomas Ferrari
1117			Ferrari Deposition, 04/02/2014 - Exhibit 02 - Hand drawn diagram of G2 filter
1118			Ferrari Deposition, 04/02/2014 - Exhibit 03 - Hand drawn diagram of the filter wire bundle, fixture, snare hook, filter jig
1119			Ferrari Deposition, 10/20/2010 - Exhibit 01 - Bard Quality Policy, Division Operating Procedure, DOPQ0700000 Rev. 3
1120			Ferrari Deposition, 10/20/2010 - Exhibit 02 - 8/17/2005 E-mail exchange b/w Stephanie Klock, Rhonda Peck, and Frank Madia Re. "ESM Packets - for PQ deployment force redo"
1121			Ferrari Deposition, 10/20/2010 - Exhibit 03 - 6/4/2004 E-mail from Uelmen to Hudnall, McDermott, Edwards, Shifrin, and DeCant Re. "Physician Panel Agenda"
1122			Ferrari Deposition, 10/20/2010 - Exhibit 04 - 9/27/2005 BPV Memo from Mickey Graves to Venus & Jupiter Snarable Filter Team Re: Project #8031 Meeting Agenda for 9/27/2005
1123			Ferrari Deposition, 10/20/2010 - Exhibit 06 - Product Opportunity Appraisal for the Eclipse Concept, POA-8113, Version 2 (pages 2-6 of 6)
1124			Ferrari Deposition, 10/20/2010 - Exhibit 07 - BPV's G2 Filter System - Femoral, Tight Spline Feasibility Report, Project No. 8048, ETR-06- 05-05 Rev. 0

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1125			Ferrari Deposition, 10/20/2010 - Exhibit 08 - Nitinol Filter Audit Plan, dated October 2005
1126			Ferrari Deposition, 10/20/2010 - Exhibit 09 - 1/4/2005 E-mail from David Zwald to many, forwarding Mark Walaska's 1/4/2005 "high" importance e-mail Re. "RNF"
1127			Ferrari Deposition, 10/20/2010 - Exhibit 10 - 5/16/2005 Memo from Loran Chapman to Kerry Chunko and Pete Palermo Re. "NEPG audit 5/12/05"
1128			Ferrera Deposition, 04/07/2017, Exhibit 01 - Robert Ferrara Curriculum vitae
1129			Ferrera Deposition, 04/07/2017, Exhibit 02 - Guiding Principles
1130			Ferrera Deposition, 04/07/2017, Exhibit 03 - Memo from Regina Busenbark dated 01/12/2006
1131			Ferrera Deposition, 04/07/2017, Exhibit 04 - Clinical Trial results from Murray Asch, MD
1132			Ferrera Deposition, 04/07/2017, Exhibit 09 - E-mail from Bob Cortelezzi dated July 5, 2004
1133			Ferrera Deposition, 04/07/2017, Exhibit 11 - Recovery Filter Arm Fracture, Remedial Action Plan September 2, 2004
1134			Ferrera Deposition, 04/07/2017, Exhibit 12 - Dear Colleague letter dated May 11, 2005
1135			Ferrera Deposition, 04/07/2017, Exhibit 13 - Dear Doctor Letter from Janet Hudnall re latest version of IFU for the Recovery Filter System
1136			Ferrera Deposition, 04/07/2017, Exhibit 16 - Presentation titled G2 Filter-Summary of Features/Benefits
1137			Ferrera Deposition, 04/07/2017, Exhibit 17 - Email from Cindy Walcott dated 11/14/2005-pricing of filter; loyal users of SNF

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1138			Ferrera Deposition, 04/07/2017, Exhibit 22 - Chart titled What is G2 trend relative to RNF?
1139			Ferrera Deposition, 04/07/2017, Exhibit 24 - Bard Memos re global PV reports by John McDermott
1140			Ferrera Deposition, 04/07/2017, Exhibit 25 - Presentation titled Filter-Fracture Analysis
1141			Fuller Deposition, 01/11/2016 - Exhibit 114 - Page of "FDA 510(k) Special Clearance Process - BARD IVC Recovery Filter", detailing the aspects of Predicate Devices, Product Design, Regulatory, FDA Clearance, and Manufacturing/Marketing
1142			Fuller Deposition, 01/11/2016 - Exhibit 115 - Presentation on Kay Fuller, RAC, including her Executive Summary, Timeline of Professional Experience, Professional Certifications and Affiliations, Education, FDA Submissions, and Publications
1143			Fuller Deposition, 01/11/2016 - Exhibit 116 - Unsigned Truthfulness and Accuracy Statement for the Premarket Notification, with Kay Fuller's signature line.
1144			Fuller Deposition, 01/11/2016 - Exhibit 118 - IMPRA Announcement Re. Kay Fuller's Entry as Senior Regulatory Affairs Specialist, Effective March 25, 2002
1145			Fuller Deposition, 01/11/2016 - Exhibit 119 - Slide from BPV's May 6, 2008 Filter Franchise Review entitled "SWOT - Objective: Increase Revenue and Capture More Market Share", detailing the internal strengths and weaknesses
1146			Fuller Deposition, 01/11/2016 - Exhibit 120 - Document entitled "Clinical Trial - Began April 25, 2000", an overview of Dr. Murray Asch's study

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1147			Fuller Deposition, 01/11/2016 - Exhibit 121 - Operative Report from the April 16, 2002 IVC Filter Removal of Patient 33 by Dr. Asch at Mount Sinai Hospital
1148			Fuller Deposition, 01/11/2016 - Exhibit 122 - RNF Failure Investigation Report, ETR-02-06-02, Rev. 01, project number unknown.
1149		9-24-18	Fuller Deposition, 01/11/2016 - Exhibit 123 - NMT Report Entitled "Line Extension to the Simon Nitinol Filter®/Straight Line System, To Be Referred As: TRADEMARK Retrievable Filter"
1150			Fuller Deposition, 01/11/2016 - Exhibit 124 - Carol Vierling's 6/21/2002 Fax to Kay Fuller with Handwritten Revisions to the RNF Failure Investigation Report, ETR 02-06-02
1151			Fuller Deposition, 01/11/2016 - Exhibit 125 - Diagram entitled "Ductile vs. Brittle Failure", with images of cup-and-cone fracture vs. brittle fracture and a graph indicating the rate of failure at increasing stress
1152			Fuller Deposition, 01/11/2016 - Exhibit 126 - 7/10/2002 IMPRA Division's Letter to FDA submitting the Special 510(k)
1153			Fuller Deposition, 01/11/2016 - Exhibit 127 - Complete Submission of the Special 510(k): Device Modification to their Simon Nitinol Filter in the form of the Recovery Filter, submitted 7/8/2002

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1154			Fuller Deposition, 01/11/2016 - Exhibit 128 - 8/5/2002 Fax from FDA to Kay Fuller, with Letter to Kay Fuller Re. K022236, Recovery Filter System (RF-048F), requesting additional information in response to the Special 510(k) premarket notification of intent, specifically on clinical testing, bench performance testing, biocompatibility, and administrative elements
1155			Fuller Deposition, 01/11/2016 - Exhibit 129 - 8/26/2002 E-mail from Kay Fuller to Mary Edwards Re. "Response Letter update"
1156			Fuller Deposition, 01/11/2016 - Exhibit 130 - Draft kf 2.1 of the Response Letter to FDA's 8/5/2002 request for additional information regarding the Special 510(k), with handwritten notes and edits
1157			Fuller Deposition, 01/11/2016 - Exhibit 131 - 11/5/2002 E-mail from Kay Fuller to Carr, DeCant, Buchanan-Kopp, Uelmen, and Edwards Re. "Post-sterilization", requesting a meeting to discuss the topic of post-sterilization/fatigue testing, which was only discussed briefly in the RF meeting that day, but was not part of the agenda
1158			Fuller Deposition, 01/11/2016 - Exhibit 132 - Authorization for Market Release for the Recovery Filter, Project No. 7081, RF048F, dated 12/20/2002, Version 000. Marked "Official Copy" and signed by all project and management teams.

Exhibit No.	Marked for ID	Admitted in Evidence	Description
1159			Fuller Deposition, 01/11/2016 - Exhibit 133 - 7/2/2003 E-mail from Lisa Kennell to Mary Edwards Re. "Clarification requested", requesting that Edwards clarify if the bench testing described in K022236 and the animal/clinical testing described in K031328 involved sterilized samples and were tested at baseline or after sterilization and aging.
1160			Fuller Deposition, 01/11/2016 - Exhibit 135 - Printout from 510(k) Decisions.com, with the FDA 510(k) Applications Submitted by Kay Fuller, RAC, with the Recovery filter being her only submission for Bard
1161			Fuller Deposition, 01/11/2016 - Exhibit 136 - Screenshot of the "Partial Product Experience List section" on Medical Device Regulatory Solutions, LLC's website, printed 10/14/2015
1162			Fuller Deposition, 01/11/2016 - Exhibit 138 - Special 510(k) Submission for the Recovery Filter System, K022236, dated 11/27/2002
1163			Fuller Deposition, 01/11/2016 - Exhibit 139 - Chart of BPV Tempe's Regulatory Affairs and Clinical Affairs hierarchy, dated 1/1/2003
1164			Fuller Deposition, 01/11/2016 - Exhibit 140 - 7/24/2003 Memo from Lisa Kennell to K031328 for the BPV Bard Recovery Filter System RF- 048F Re. "Summary of file and recommendation". Recommendation: The device can be cleared to market for retrieval, with the modified labeling submitted electronically on 7/23/03".
1165			Fuller Deposition, 01/11/2016 - Exhibit 141 - 6/14/2002 E-mail exchange b/w Carol Vierling and Susan Alpert, with others, Re. "FDA Request -- SNF"